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VIII EVALUATION OF THE BIOMOLECULAR ENGINEERING PROGRAMME, BEP (1982-6) AND 
THE BIOTECHNOLOGY ACTION PROGRAMME, BAP (1985-9) 
°- Executive summary : description, conclusions, recommendations, 
methodology. 
0.1. Programme description 
0.1.1. The first Community programme in biotechnology, BEP, was proposed 
by the Commission in 1979. It was approved by the Council on 7 
December 1981 with a budget of 8 Mecu
1. The programme was 
revised by the Council on 26 October 1983 and an additional 7 
Mecu was provided
2. 
0.1.2. The programme ran from April 1982 to March 1986. It contained 
two activities, research, which involved 50X support through 
contracts for some 103 projects, conducted largely in 
universities and public laboratories, and training, through 
fellowships awarded to some 77 Community scientists to spend 1-2 
years in a laboratory in another Member State. 
0.1.3. The research was sub-divided in five sectors : 
- second generation bio-reactors 
- animal husbandry and agro-food 
- upgrading of plant products, particularly ligno-cellulose 
- plants and organisms important for agriculture 
- contamination detection and risk assessment. 
1 0J n° L375, 30.12.81, pp. 1-4 
2 0J n° L305, 8.11.83, pp. 11-13. 0.1.4. The second Community programme. BAP, was proposed by the 
Commission in 1984. It was approved by the Council on 12 March 
1985 with a budget of 55 Mecu*. The programme provided for a 
continuation of the research and training activities and aimed 
at: 
- the establishment of a supportive infrastructure for 
biotechnology research in Europe; 
- the elimination of bottlenecks which prevent the exploitation 
by industry and agriculture of the methodologies originating 
from modern biology. 
Uork was divided into a number of sectors under each 
subprogramme, as follows : 
Subprogramme I : Contextual Measures 
Bio-informatics 
Culture collections 
Subprogramme II : Basic Biotechnology 
Enzyme engineering 
Genetic engineering of agricultural species 
Cellular and genetic engineering of microbial species 
important to industry 
Sisk Assessment 
Genetic engineering for animal husbandry / novel methodologies 
of animal cell cultures 
In vitro evaluation of the toxicity and of the pharmacological 
activity of molecules. 
BAP also introduced a new element, concertation, with the 
objectives of "improving standards and capabilities in the life 
sciences, and enhancing the strategic effectiveness with which 
these are applied to the social and economic objectives of the 
Community and its Member States". Nine specific tasks were 
allocated to a special unit (the Concertation Unit for 
Biotechnology in Europe, CUBE). 
* O.J. N° L83, 25.3.85, pp. 1-7 0.1.5. The research work has continued to be mainly of a fundamental 
character conducted in public laboratories with open publication 
of the results. However applicants for contracts were required 
to form partnerships with laboratories in other Member States, 
and were also encouraged to seek written "expressions of 
interest" from industrial firms. 
0.1.6. Under BAP, some 262 research contracts have been awarded to 
laboratories grouped in 95 projects. There were 169 "expressions 
of interest" from industry, but only 16 of the contractors were 
actually industrial firms. Some 189 fellowships have been 
awarded, the majority to relatively junior scientists (pre-
doctoral or just post-doctoral). 
0.1.7. Currently, the Commission are seeking a "revision" of BAP, which 
would provide an additional 20 Hecu to be committed up to the end 
of 1989. This would be used particularly for : 
- research on risk assessment 
- research on the application of information technology to 
biotechnology, including culture collections, genome sequences 
and protein modelling 
- research contracts for Portugese and Spanish laboratories (who 
were not strictly eligible for most of BAP) 
- a doubling of the training programme 
- an increase in the staff of CUBE. 
0.1.8. The third Community biotechnology programme. BRIDGE 
(Biotechnology Research for Industrial Development and Growth in 
Europe) is now in preparation. The Council have earmarked 100 
Mecu for this in the second Framework Programme that was adopted 
last September*. In parallel with BRIDGE, there are or will be a 
number of other cost-shared research programmes relevant to 
* O.J. L302, 24.10.87, pp. 1-23 biotechnology, listed below together with their budgets : 
agro-industrial, ECLAIR
5 80 Mecu 
food-linked agro-industrial, FLAIR* 25 Mecu 
tropical agriculture and medicine, STD2
7 80 Mecu 
agricultural competitiveness and resource use 55 Mecu 
Some other programmes (medicine, non-nuclear energy/biomass, 
environment, SCIENCE) also include sectors relevant to 
biotechnology. 
0.1.9. The biotechnology programmes (including CUBE) are administered by 
some 11 professional staff of the directorate for biological 
resources within DG XII in Brussels. 
0.2. Conclusions 
0.2.1. Ue consider that the research programmes have been well 
administered by a competent and enthusiastic Commission staff. 
They appear to have supported work of a good scientific standard, 
which has led to genuine trans-national scientific cooperation in 
Europe. The system for selection of contractors struck us as 
fair, if rather cumbersome, and it was based primarily on 
scientific merit. The process of contract negotiation seems to 
us often to have been slow, particularly in view of the rather 
small sums involved. But many witnesses told us that the 
monitoring of the work by the Commission staff had been very 
good, although they had not had enough time to visit all the 
contractors at an early stage. The contractors' and sectoral 
meetings appear to have been exceptionally well-run and useful. 
0.2.2. The programmes have certainly contributed in a significant way to 
β European Collaborative Linkage of Agriculture and Industry through 
Research 
* Food-Linked Agro-Industrial Research 
7 Science and Technology for Development, second programme. the establishment of a supporting infra-structure for 
biotechnology research in Europe. Furthermore they have led to a 
number of substantial scientific achievements, as shown by the 
high level of citations and degree of transnationality. However 
we consider that the programmes' objectives were over-ambitious 
for the resources available, which were reduced by the Council. 
Horeover in some sectors goals to be attained and bottlenecks to 
be removed were insufficiently defined, and consequently 
significant breakthroughs were not made, perhaps because a 
critical mass of researchers was not assembled. In other sectors, 
such as the genetics of plants and of industrial micro-organisms, 
where goals were specified, some highly significant technical 
breakthroughs were indeed achieved, see Annex 3. 
0.2.3. We have concluded that a major achievement of the research 
programmes, and one that is important for the future, has been to 
break down national frontiers between laboratories. Ue commend 
the Commission's initiative in linking groups into European 
Laboratories Uithout UaiIs (ELUUs), a useful concept that could 
be applied in other domains. Ue were impressed by the way some 
contractors, who had initially been sceptical about trans-
national cooperation, were now enthusiastic. Indeed, 
transnational cooperation, once begun, may prove easier than 
national cooperation because the researchers are usually not 
direct competitors. There is evidence from our bibliometric study 
(see Annex 6) that BEP has brought about a significant increase 
in transnational cooperation among its contractors, and this 
trend must have been strongly reinforced under BAP. 
0.2.4. Nevertheless, there have remained too many small unrelated 
projects. The size of most contracts (averaging 50,000 ecu/year), 
despite their undoubted value to certain research groups, was 
often too small to attract either significant industrial 
participation or (in some cases) leading academic groups in 
Europe. Because of the small size of the contracts it was very difficult for us to identify how much has been achieved by a 
group that would not have occurred anyway, albeit perhaps 
slightly later. 
0.2.5. Although there have been many "expressions of industrial 
interest", few firms have actually participated in BAP as 
contractors, and of these, even fewer are large. According to our 
survey (see Annex 2, 2.4.4-2.4.10) even now, almost two-thirds 
of European biotechnology firms claim to have insufficient or no 
information about the EC programmes. Another reason why firms may 
not participate is that in biotechnology even quite basic 
research may lead to patentable, and therefore commercially 
valuable, inventions. Industry fears that patent protection may 
not in fact be secured because of academic interest in 
publication. The consequence has been that industry has been shy 
of participating in the scientific meetings for fear of revealing 
too much, and on some occasions may not have been welcomed by the 
contractors from academe. Conversely, some of the work has been 
conducted by contractors without enough knowledge of what would 
be useful for industry, or indeed of whether industry has not 
already covered the same areas with its generally greater 
resources. However, many of the research groups told us that 
they had well-established contractual links with individual firms 
on a proprietary basis : there are therefore routes whereby 
commercial exploitation could occur. 
0.2.6. From our many interviews with the fellows, their supervisors, and 
former fellows under BEP (see Annex 4), we have concluded that 
the training programmes have been successful. We have noted the 
good standard of the fellows, and of the training they have 
received, the utility of the fellowships in helping them obtain 
employment, and the continuing transnational links between 
fellows and their host laboratories. Ue found that virtually all 
the fellows were glad to have stayed in Europe, rather than going 
to the USA, and this augurs well for future European linkages. 0.2.7. However ue think that the training programme is currently poorly 
marketed and therefore undersubscribed, and ue discovered that 
contact between the fellows and the Commission is minimal. The 
fellows are not well informed about the European Community and 
its work in biotechnology, and some of them see little of their 
host country except the lab in which they work. 
0.2.8. The concertation activity has been characterised by an enormous 
volume of work, but although there have been some successes (the 
new sugar and starch regimes, and the ECLAIR proposal, for 
example) there have also been some failures (lack of agreement on 
the approach to a European regulatory regime, little use of the 
elaborate data base, poor public understanding of the advantages 
of biotechnology and the nature of the attendant risks, no 
coordination of inputs from other DGs to the research carried out 
in BAP). The problem seems to have been that the concertation 
tasks were too numerous, and more difficult than was originally 
realised. The lack of permanent secretarial assistance for CUBE 
has also been a handicap. The consequence has been that CUBE'S 
efforts have been dissipated too widely, and it has not had 
enough time to look at some important longer-term issues. 
0.2.9. Biotechnology research is a highly competitive activity world 
wide. The European position is currently quite strong in some 
sectors, e.g. plant science, but is weak in others, such as 
microbiology. It is clear that a continuing investment in 
fundamental scientific understanding is needed for commercial 
success. It is also clear that, although some commercial 
developments will occur fairly soon, others will require a decade 
or more to come to fruition, notably in plant science where much 
work remains to be done on plant physiology. Industrially, a 
major European weakness, with limited exceptions, is the lack of 
vitality of the small science-based firm sector. Most of the 
industrial research takes place in large companies, but they are, as noted earlier, little involved in the EC research programmes. 
0.2.10. Two European handicaps relative to the US were repeatedly 
mentioned to us, namely the lack of a soundly-based common 
regulatory regime, and uncertainties on intellectual property 
rights (IPRs). These are serious "bottlenecks" preventing the 
exploitation of the European scientific strengths. 
0.3. Recommendations 
0.3.1. We recommend that the research programme of BRIDGE should be 
divided into three parts. The main part, which should absorb 45% 
of the total budget, should be clearly focussed and directed 
towards the solution of major trans-European problems through 
large-scale projects. The second part, with 25% of the budget, 
should consist of science-led projects in response to an open 
call for proposals. We have given some specific suggestions in 
Annex 3. The third part, with 5% of the budget, should be 
coordinated action, building on the existing COST 48 and COST 87 
Projects, in which the Commission would pay only for scientific 
meetings and short-term exchanges. We recommend that the 
Commission should also seek to use the fellowships from the 
training programme to provide additional support for these 
cooperative projects and for those ELWWs that show promise. 
0.3.2. The large-scale part of the research programme should involve a 
limited number of major multi-disciplinary projects. The 
Commission should appoint an external or internal project manager 
for each project. Each project should have a budget sufficient to 
support a critical mass of researchers. Individual contracts 
should be large enough to attract high quality European research 
laboratories, including industrial firms where appropriate. 
Nevertheless, in most areas it would not be appropriate to insist 
on industrial contributions, although active participation 
through secondment of industrial staff to research centres should 
8 be encouraged. Where industrial contributions are required, we 
recommend that the Commission should take account of the size of 
the participating firms and set stiffer targets for large 
companies. 
0.3.3. Among the large-scale projects that we consider should be the 
subject of particular initiatives are the following : 
1. To sequence the yeast genome completely. 
2. To develop detailed molecular genetic maps for one plant and 
one animal species of economic importance to Europe. 
3. To undertake a focussed programme in protein engineering so 
as to understand and modify in a multi-disciplinary manner 
the structure and biological and/or physical properties of a 
few proteins. 
4. To elucidate the control of gene stability, transcription, 
post-transcriptional and post-translational processing, 
protein over-production, and secretion in one major 
industrial micro-organism through genetic manipulation, 
biochemistry and cell physiology. 
5. To apply recent progress in molecular biology to the 
physiology and improvement of major European crops, including 
gene transfer to, and cell regeneration of, cereals. 
6. To establish a complete interconnexion and cataloguing system 
for the major culture collections in all Member States with 
on-line access, for a fee, by all research workers. A pilot 
scheme, involving the current BAP contractors, should achieve 
these objectives by 1991. 
7. To continue to develop appropriate methodology for an 
assessment of the safety and ecological consequences of the 
release of genetically-modified organisms, especially 
bacteria and viruses, in order to develop guidelines for best 
practice in the production and use of such organisms. 
Except where noted otherwise, the above goals should be attained 
by the end of the BRIDGE programme, and most of them by 1994. 0.3.4. Ue recommend that these large-scale research projects should be 
organized through a framework developed by the appointed project 
manager in close cooperation with the Commission' services. This 
framework should be used to invite applications from potential 
contractors, or consortia of appropriate laboratories, from 
throughout the Community. The strategy for each project, and the 
individual proposals, should be appraised by ad hoc committees 
invited by the Commission that include industrial experts and 
members of other Commission services as appropriate. The 
selection criteria should be based on scientific merit and 
relevance to the project goals. 
0.3.5. The training programme should be expanded to absorb 15% of the 
total budget of BRIDGE and provide about 50 grants per year. It 
should be more vigorously promoted, with a target of at least 
four candidates per fellowship. The normal tenure should be two 
years, extendable exceptionally to three. The objective of the 
fellowships should be to provide training in disciplines 
currently in critical supply, either locally or throughout the 
Community. 
0.3.6. The training programme should be managed by at least one full-
time professional staff member. Short-listed candidates should 
be asked to attend an interview and briefing in Brussels before 
appointment. The fellowship manager should maintain contact with 
all fellows during their tenure and hold occasional informal 
meetings of fellows in a Member State or region. He or she 
should also maintain and publish a directory of all EC 
biotechnology fellows, past and present, and their supervisors. 
0.3.7. The level of monthly payments to the fellows should be reduced by 
10%. However the money saved should be used for an approved 
programme of travel primarily within the host country, occupying 
about two weeks per year of tenure. Bench fees should be paid in 
10 respect of junior fellows, as well as for senior ones, and 
negotiated with host laboratories. 
0.3.8. The concertatjon activity should also be expanded in line with 
the general growth of the biotechnology research programme, to 
about 10% of the total budget of BRIDGE. Ue propose that Task 
Forces for major initiatives which involve the work of several 
DGs should be created as necessary. The need for such task forces 
could be identified by CUBE, but they would be distinct from CUBE 
as at present constituted. They would be temporary and report to 
the Commissioner for Science Research and Industrial Affairs. 
They would need a leader of sufficient status to ensure effective 
decision-making. The operating cost of these Task Forces would be 
paid from the 10% earmarked for concertation. 
0.3.9. CUBE should concentrate on four major tasks, of which the last is 
new : 
1. The coordination of the Commission's approach to 
biotechnology, including the dissemination of information 
internally (currently task 3), and the formulation of 
proposals for future initiatives. 
2. The concertation of biotechnology activities of Member 
States. 
3. The provision of information on the advantages, limitations 
and safety of biotechnology to politicians, scientists and 
the general public in the Community and in Associated States 
under the Lomé Convention (currently tasks 6 and 8). 
4. Activities designed to promote the formation and growth of 
small and medium-sized biotechnology firms. 
0.3.10. In order to undertake the third task, CUBE should recruit one or 
more experts in communications and should devote funds to the 
production of suitable educational and other material, including 
translations. 
11 0.3.11. Ue recommend additionally that the research programme in 
biotechnology should be opened to the EFTA countries, on a 
programme or project basis, so that leading research teams in 
these countries may be integrated in the European scientific 
networks, as they have been under the two COST Projects. 
0.3.12. Ue have advocated a focussed programme emphasizing carefully 
selected goals. Ue must note, however, that important sectors of 
biotechnology, such as separation technology, downstream 
processing and health biotechnology, are not at present covered 
in the BAP programme. Furthermore, the overall level of funding 
is inadequate to support the expanded coverage and intensified 
effort which are necessary for Europe to be competitive in the 
important and rapidly evolving field of biotechnology. Therefore, 
given the long-term strategic importance of the subject, we 
strongly recommend that the funds for biotechnology should be 
increased in the revision of the Framework Programme expected 
during 1989. 
0.4. Methodology 
0.4.1. Ue were appointed to serve on the evaluation panel as individuals 
and not as representatives of countries or institutions. 
Nevertheless our varied nationalities (D, F, GR, I, NL, S, UK) 
and backgrounds (four of us have academic posts, three are or 
have been in Government, and two in industry) have helped us to 
understand the programmes. Our terms of reference are set out in 
Annex 1. Ue have tried to keep them constantly in mind but have 
not attempted to answer every question mechanically. 
0.4.2. Ue have, in particular, concentrated on the impact of the 
programmes and certain organisational issues, rather than the 
scientific merit of the individual projects. Our principal 
source of evidence has been personal interviews, but we have also 
been given access to many reports published by the Commission's 
12 programcne managers and other literature (see Annex 8). During the 
evaluation, we have met five times in Brussels as a panel, and we 
have undertaken missions in groups of three, totalling 17 days, 
to eight Member States. These missions afforded us time to get 
to know each other well, and helped us to work together 
effectively as a group. We commend the method to other 
evaluation panels. 
0.4.3. In Brussels, we have received presentations from, and had 
individual discussions with, all the programme managers. Ue have 
had meetings with the current and two past CGC chairmen, and with 
C6C delegates from ten of the twelve Member States. Ue have also 
met Commission officials from DGs III, VI, VIII, XI and XVII. 
0.4.4. During our missions we arranged interviews, typically of 3/4 
hour, with some 84 contractors or their representatives. Most of 
these were in central locations but we were also able to visit a 
few laboratories to see work in progress (mostly in the plant 
sector). We interviewed some 23 current fellows and 21 
supervisors, and also 9 former fellows under ΒΕΡ; these 
interviews typically only lasted 20-25 minutes but they gave us a 
valuable insight into the training programme (see sections 4.4, 
4.5, 4.6). We were rather less successful in securing interviews 
with industrialists and have commented elsewhere on this paucity; 
nevertheless we managed to see 24 of them, including several 
members of the IRDAC Working Party on biotechnology. 
0.4.5. In order to study on a more quantitative basis the main output of 
BEP, namely scientific publications, we asked for a small 
bibliometric study to be carried out for us by the University of 
Manchester. A synopsis of the results is given in Annex 6. The 
purpose of the study was essentially two-fold : 
- to see if BEP papers were more transnational than other 
biotechnology papers with EC authors; 
- to see, through their citation record, if BEP papers had had a 
13 significant impact on other scientists. 
0.4.6. Ue received written representations from 13 external 
correspondents, following the circulation to the technical press 
and to biotechnology associations of an open invitation to 
interested parties to submit evidence. Ue circulated a written 
questionnaire to former BEP fellows whom we were unable to meet, 
and received 21 replies. Ue also sent out a written 
questionnaire to some 210 industrial firms, most of whom had not 
been involved with the programmes, to ask why not : we have so 
far received replies from 60 (see section 2.4.). 
0.4.7. A full list of all the witnesses who kindly made themselves 
available to see us, and those who took the trouble to write to 
us or return our questionnaires, is given in Annex 7. Ue should 
like to express our appreciation of their help, and to record in 
particular our thanks to all the programme managers who were 
unfailingly courteous in their responses to our enquiries and in 
the provision of help. Ue would also like to add to this our 
thanks to Mr. Luigi Massimo, Head of the Evaluation Unit, and to 
our Secretary, Dr. Grant Lewison, who has applied a continuing 
enthusiasm and professionalism to the vital job of organizing the 
work of this panel. The task of evaluation has been positively 
agreeable, largely because of the warm and friendly reception 
that we have been accorded both in Brussels and during our 
travels, notably in several of the Commission's press and 
information offices in Member States. 
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15 16 ANNEX 1 
TERMS OF REFERENCE AND MEMBERSHIP 
1.1. The panel is composed of persons who are appointed by the Director 
General for Science, Research and Development (DG XII), as 
individuals and not as representatives of particular organizations 
or countries. Their views in no way commit their employing 
organizations. They are required to keep confidential any evidence, 
written or oral, submitted to them that witnesses indicate should be 
so treated. 
1.2. The panel is to evaluate the Biomolecular Engineering Programme, 
April 1982-March 1986 (BEP), and the Biotechnology Action Programme, 
January 1985-December 1989 (BAP), although the latter is still in 
progress. 
1.3. The panel is to assess : 
1.3.1. the scientific and technical achievements of the programmes 
taking into account their original objectives and milestones, and 
whenever relevant of changed circumstances; 
1.3.2. the quality and practical relevance of the results including 
(whenever relevant) commercial development and exploitation, and 
possible spin-offs; 
1.3.3. the effectiveness of management and of the use of ressources; 
1.3.4. the programmes' contribution to the development of Community 
policies and to the social and economic development of the 
Community; 
1.3.5. the benefits resulting from the implementation of the programmes 
at the Community level (Community added value). 
17 Quantitative indicators will be used whenever appropriate. 
The panel's assessment of achievements and benefits should take into 
account the expenditures applied. 
1.4. The evaluation should lead to recommendations on the following : 
1.4.1. the future continuation, alteration, or termination of 
biotechnology research by the Community; 
1.4.2. the management of the programme; 
1.4.3. the use of research results by organizations carrying out the 
work; 
1.4.4. the transfer of technology to other organizations, by movements of 
personnel, by licensing, and by other means. 
1.5. The panel, in making its assessment of the programmes' achievements, 
should give particular attention to the following questions : 
1.5.1. whether the programmes have brought or are likely to bring about 
several highly significant breakthroughs; 
1.5.2. whether the programmes have already attracted the interest of 
European industrial firms, as shown by their participation in 
projects and recruitment of scientists who have worked on them, 
and whether at least half the projects are likely to lead to 
additional development expenditure by European industrial firms of 
sums greater than the total expenditure on projects supported by 
the programmes; 
18 1.5.3. whether the work supported by the programmes has removed or is 
likely to remove previously identified "scientific bottlenecks" 
and in particular has led or will lead to : 
- significant improvements in fermentation technology; 
- neu or improved germ plasm which could be introduced in 
breeding programmes for the development of crops needed for a 
market-related agriculture in Europe; 
- neu or accelerated methods to produce plants and seeds for 
commercial sale; 
- the detection, prevention, or treatment of diseases of farm 
animals or agricultural crops; 
- improvements in the safety and quality of animals and crops for 
consumption or processing; 
- solutions to environmental problems; 
- improvements in the time, cost, and level of assurance for the 
demonstration of the safety of neu biotechnological products 
and processes; 
- improvements in the testing of neu products on cell cultures 
rather than animals; 
- the scientific basis for neu or improved regulations governing 
biotechnology in the European Community or in individual Member 
States. 
1.5.4. whether the training provided to the trans-national fellows has 
been given by laboratories of high scientific quality and whether 
the fellows are subsequently employed in Europe where they can 
make good use of their training; 
1.5.5. uhether the programmes have led to effective trans-national 
collaboration on a continuing basis betueen scientists and 
laboratories in different Member States, uhether there has been an 
increase betueen 1981 and 1986 in the proportion of scientific 
papers in leading journals in biotechnology published by 
19 laboratories participating in the BEP that have authors from more 
than one Member State, and if so, what proportion of this increase 
can be attributed to the programmes; 
1.5.6. whether there is clear evidence of trans-national marketing of 
biotechnology research facilities, resources and support services 
in the Community as a result of sub-programme 1 of the BAP, and 
whether this is leading to increased trans-national demand for 
such services; 
1.5.7. whether the concertation activity has effectively executed the 
nine specific tasks listed (as Action II of the Council Decision 
of 12 March 1985) and whether through these activities or 
otherwise this action has enhanced the application of 
biotechnology to the social and economic activities of the 
Community and its Member States. 
1.6. Subject to the prior approval of the Commission, the panel members 
may travel within the Community to interview persons about the 
programmes and to see work in progress. Subject to the same 
approval, the panel may also retain consultants or experts in order 
to examine particular questions in detail. 
1.7. The panel is required to produce a report by 30 June 1988. This 
report will be published by the Commission. The panel may also 
prepare a confidential annex for the Director General of DG XII if 
it feels that this is desirable and necessary. 
20 1.8. List of panel members 
Chairman 
Dr Charlotte AF MALMBORG (S) 
Department for biotechnology and life sciences 
Swedish National Board for Technological Development 
Stockolm 
Members : 
Dr Pierre FEILLET (F) 
Institut National de la Recherche Agronomique 
Montpellier, France 
Professor Fotis C KAFATOS (GR) 
Biological Laboratories, Harvard University, USA 
and Institute of Molecular Biology and Biotechnology 
Heraklio, Crete 
Professor Dr Jan KOEMAN (NL) 
Department of Toxicology, Agriculture University 
Uageningen, Netherlands 
Dr Paolo SAVIOTTI (I) 
Department of Science and Technology Policy 
University of Manchester, England 
Professor Dr Günther SCHMIDT-KASTNER (D) 
Bayer AG, Wuppertal, Federal Republic of Germany 
Dr Geoff WALKER (UK) 
BASE International Ltd, Milton Keynes, England 
21 22 ANNEX 2 
GENERAL OBSERVATIONS ON THE PROGRAMMES 
2.1. Evaluation considerations 
2.1.1. Any programme has strategic goals, an internal organisation or 
structure, and produces impacts. All three can be evaluated ex-
post, and the first two can, in principle, be appraised ex-ante. 
Different evaluation criteria »ill be appropriate for the three 
aspects of the programme. Thus for the goals, one can consider 
whether they are correct, appropriate and consistent; for the 
structure, one can describe and parametrise the mechanisms; for 
the impacts, one can list the types of benefit-social, economic, 
etc. 
2.1.2. For BEP, the stated goal was the removal of bottlenecks 
preventing application of molecular and cellular biology to 
agriculture and the agro-food industry. The structure consisted 
of shared cost research contracts, contractors' meetings, and 
training contracts. The expected benefits were the removal of 
these bottlenecks, a general improvement in European scientific 
capability in biotechnology, and transnational cooperation. For 
BAP, the research goals were extended to include the improvement 
of the infrastructure and better means of risk assessment, and 
certain other goals involving concertation were added. An 
additional structure, namely CUBE, was provided. The benefits 
should also have included the construction of a European 
infrastructure in bio-informatics and for cell cultures, and 
better knowledge and control of bio-hazards deriving from 
biotechnology. 
2.1.3. The criteria for the evaluation of the goals of a research 
programme are not absolute, but they have to fit with the general 
economic and political goals of the programme sponsor, here, the 
Commission. Under the second Framework Programme for R&D adopted 
23 by the Council in September 1987, there are five conditions under 
which Community action can be justified : 
- When the work contributes to the cohesion of the Community and 
to its harmonious development. 
- Where the work is on a large scale so that individual member 
states could not otherwise afford it. 
- Unen the work would save money through avoidance of 
duplication. 
- Uhen the work addresses trans-national problems and requires 
coordinated efforts (e.g. on pollution). 
- Uhen the work contributes to the achievement of the Common 
Market e.g. through standards. 
Goals should also be coherent and verifiable. For scientific 
programmes, the consideration of the goals should take into 
account the development of the relevant science, and of the 
associated technology, as discussed below. 
2.1.4. The criteria for the assessment of programme structure involve 
the detailed description of the procedures used to implement the 
programme, with numerical data. Thus for the research contracts 
information is needed on : 
- total number of contracts 
- distribution by technical sector 
- distribution by type of contractor (university, industry, etc) 
- distribution by country 
and for each contract : 
- duration 
- value 
- number of participants 
24 - contact with industry 
- subsequent trans-national activity of participants. 
For the contractors' meetings one needs to know : 
- number of meetings and topics 
- participants at each, including contractors, industrialists and 
others. 
For the training programme, the examination should cover : 
- distribution by duration, and senior/junior level 
- total number of fellowships 
- matrix of fellow's country/host country 
- criteria used for selection 
and for each fellowship : 
- the scientific reputation of the institutions involved 
- previous experience of fellow 
- experience of fellow during training (problems, publications, 
etc.). 
2.1.5. The impacts and benefits should be fairly straightforward to 
evaluate if the goals have been stated in a verifiable form. 
Several types might be considered : 
- scientific, through the effect of the research on other 
scientists, e.g. through their citation of publications and 
other measures of esteem; 
- economic, through the development by industry of new products 
and processes, although this may not occur for some years and 
even then the link may be indirect; 
- social, through the formation of intra-community links for 
research and other purposes. The improved cohesion of the 
Community's less-developed regions with the rest should also be 
considered. 
However it is important that there should be a plausible link 
between the means used to implement the programme and the 
expected benefits. 
25 2 1 6 Ue next consider son* general points on technological change that 
pertain to the evaluation of BEP and BAP. Biotechnology is not 
a single technology but a series of technologies all of which use 
biological materials as inputs. The span stretches from 
traditional fermentation processes (cheese, wine) to protein 
engineering whose products are barely emerging. Now several 
theories of technological innovation postulate a series of 
qualitatively-different stages : 
- emergent : heavy dependence on basic science, variety of 
organisations involved, slow growth of sales; 
- new : many product designs, incomplete technology, sales expand 
rapidly; 
-mature : dominant design, well-established processes and 
organisations, sales growth reduced, but possibility of 
technology rejuvenation exists 
- obsolete. 
The above model can help us to assess the prospects for 
development of different technologies. Ue should also be aware 
that, although technology is visibly embodied in machinery and 
goods, which constitute the revealed technological performance of 
the industry, it depends equally on the «knowledge base" of 
industry, i.e. individual skills, design and operational 
procedures, and communication patterns. The competitiveness of 
industry depends at least as much on the latter, especially in 
the early stages of the innovation process. 
2.1.7. individual firms can choose between a number of innovation 
strategies
1 : 
- offensive 
- defensive 
- imitative 
ι Freeman, C "The economics of industrial innovation", Francis 
Pinter, London, 1982. 
26 - dependent 
- traditional 
- opportunist 
The higher up the list a firm chooses to go, the more it will 
depend on a high level of research and development in order to be 
first to bring a new product to market. It is valid to consider 
what is the most appropriate innovation strategy, not only for an 
individual firm, but for European industry as a whole. 
2.1.8. Ergas* has classified rational technology strategies as mission-
oriented or diffusion-oriented. The former Implies the support 
of large projects, such as for defence procurement. The latter 
implies the aim of spreading awareness of neu technology to many 
firms in the sector so as to enable them to use best 
technological practice. Finally, new technologies may be limited 
in their application, or of value in many industrial sectors, 
when they are sometimes called "generic". An example is 
microelectronics. 
2.1.9. We are thus led to ask the following questions : 
- Is biotechnology sufficiently homogeneous that a common policy 
can be defined at the national or European level ? If so, can 
a life cycle be defined and its present position identified ? 
If not, can we do this for different sectors such as brewing 
and the production of monoclonal antibodies and identify the 
the likely influence of research and consequent benefits? 
- Do we need to choose a pattern of specialisation at either the 
national or European level ? 
We note that in biotechnology the USA appears strong in the 
application of recombinant DNA techniques in pharmaceuticals and 
diagnostics, and Japan in industrial fermentation for fine 
a Ergas, H. "Does technology policy matter?" OECD, Paris, July 
1986. 
27 chemicals and the food industry, whereas Europe has strengths in 
antibiotics and plant science. 
- Should Europe aim to remain a leader in selected areas and 
concentrate its research efforts there ? If so, how much work 
is needed to keep abreast of developments elsewhere in other 
sectors ? 
- How strong is the "knowledge base" of European research 
institutes and industrial firms, both individually and trans-
nationally, in comparison with their competitors elsewhere ? 
(This implies a careful monitoring of research capabilities.) 
- Is it important or necessary to adopt different innovation 
strategies (see Freeman, op. cit.) for different sectors of 
biotechnology either at the national or European level, bearing 
in mind that the Member States vary in their degree of 
development ? 
2.1.10. In summary, it seems appropriate that the strategy for 
biotechnology in emergent and new sectors should be flexible, and 
be based on an analysis of existing developments. On the other 
hand, a strategy for more mature sectors, where the development 
patterns are clearer, could involve the concentration of 
resources on a few large projects. Similarly, it would be wise 
to restrict decisions about patterns of specialisation to these 
more mature sectors. 
2.2. Overview of BEP and BAP 
2.2.1. From written and oral evidence to the panel we agree by and large 
with the analysis of the programmes made by the staff of the 
Commission. The scientific quality of the work is very good, 
shown inter alia by the number of publications in renowned 
scientific journals. The degree of transnationality achieved is 
impressive. Many contractors express a clear opinion about the 
importance of going European. Hence, two of the main goals from 
28 the onset have been reached. 
2.2.2. In BEP the main topic of interest was genetic engineering for 
agriculture. The topic with least attraction was risk 
assessment. The same tendency is prevalent in BAP «here the 
majority of contracts are on the biotechnology of microorganisms, 
plants and animals and there are still few on risk assessment. 
This reflects the worldwide interest in molecular biology 
instilled by the economic prospects attributed to this area. 
However the road is long, costly and full of pitfalls before a 
commercial product can be brought to market. 
2.2.3. To what extent scientific bottlenecks preventing the exploitation 
of modern biology have been eliminated through BEP and BAP is 
hard to say. Our impression is that the scientific merits are 
more dominant than the industrial ones. Few industrial firms 
have in fact been active in the contracts. The reasons for this 
include the small size of the contracts, the lack of information 
to industry, the emphasis of the programmes on basic long term 
research, fears about loss of IPR, and the reluctance of some 
firms to do research with their competitors. There was also a 
lack of commercially-oriented and verifiable goals. As the work 
under the BEP and BAP was intended to be precompetitive, 
verifiable goals would have been difficult to define. The aim of 
BEP and BAP was to introduce new knowledge, and so the goals had 
to be science-driven. For BRIDGE, however, conditions are more 
favourable for a major part of the work to be objective-led. 
2.2.4. Uhen goals cannot act as steering signals coordination activities 
become more important. Here the programme managers have played a 
key role. Ue are impressed by their drive, enthusiasm and skill 
in running the programmes. This is confirmed by the witnesses we 
met. The programme managers' efforts are highly appreciated. 
They have effectively contributed to the establishment of the 
European network in biotechnology which is now in existence. 
29 This has been achieved by the collaboration itself as well as by 
the different initiatives taken by the programme managers : 
- establishment of the ELUUs (European Laboratories Without 
Halls) 
- arrangement of sectorial meetings 
- programme managers' visits to contractors 
- programme managers' attendance at sectorial and other 
scientific meetings 
- invitations to leading experts in the world to meet and discuss 
with the contractors 
- efforts to convey the message that there is more behind the 
Commission than just money. 
2.2.5. Scientists have and should have one thing in mind - to pursue 
their science, so they look for resources. Quite naturally BEP 
and BAP meant to them from the beginning chiefly a new source of 
money. Indeed, although the Community Biotechnology programme is 
relatively small, it is impressive how important it has become 
for even some of the best research groups in Europe, because of 
its flexibility and its awarding on the basis of merit. An 
additional widely recognised value of the programme is its 
transnationality. Without the coordination activities by the 
Commission's services this would not have been possible. On the 
national side CGC delegates and national programme managers have 
contributed by their involvement in the selection procedure for, 
and the marketing of, the programmes. 
2.2.6. We regard the selection procedure as fair but too cumbersome. 
Under BEP 103 contracts were negotiated from 293 applications. 
Under BAP the figures were 262 and 1357 respectively. Fears were 
sometimes expressed to us about the work load in coming 
programmes. This is one reason why we believe that a major part 
of BRIDGE should comprise a limited number of major multi-
disciplinary projects. 
30 2.2.7. The relationship to national or to other Community programmes is 
not clearly specified. On the national level it is important 
that the support is complementary to the Community's. There 
should not be a reduction of funding on the national level for 
contractors who have been successful on the EC level - a fear 
which was expressed in several countries. On the Community level 
it is important not to divide the resources among too many small 
projects so the contracts become subcriticai in size. Also good 
applications may have to be turned down if they do not fulfil the 
requirements set out. 
2.2.8. The marketing both of the scientific and the training programmes 
could probably be more systematic and thus more efficient. 
Opinions expressed by some witnesses were that 
- not all good scientific groups are involved 
- the topics are not all of true European interest 
- the number of applications for training grants is too small to 
permit a rigorous selection among candidates (see Annex 4, 
section 4.1.4). 
2.2.9. It has been difficult for us to get a clear view of to what 
extent industry has adopted the results from BEP or BAP. Ue have 
met only a few industrialists. They were positive about the 
existence of the programmes but did not express a deep 
commitment, and some were concerned that the industrial relevance 
was weak. Therefore we consider that it is important to involve 
industrialists in the future selection procedure, as is planned 
for BRIDGE. 
2.2.10. Under BEP, twelve patent applications were filed and under BAP, 
contractors are encouraged to protect their results through 
patenting. Here a note of warning may be appropritate. It 
should be borne in mind that the role of a patent is to protect 
an invention and not new knowledge. To file an application and 
to hold a patent costs money. Patent expertise and the necessary 
31 financial resources should be sought as soon as it becomes 
apparent that an invention has been made. In biotechnology it 
has often been claimed that commercialization follows closely on 
the scientific result but this is in fact rare. 
2.2.11. An even more important obstacle for commercialisation of 
biotechnology in Europe is the lack of appropriate and uniform 
regulations, which take into account safety as well as expected 
benefits. An important task for the future is therefore to 
achieve harmonisation of the regulatory framework for 
biotechnology in the EC Member States. He endorse the principle 
recommended by OECD that the safety of products should be 
assessed through their inherent properties and not through the 
nature of the process by which they were made. 
2.2.12. Dissemination of results from the programmes has been through 
reports, articles, papers and meetings. The meetings have been 
highly appreciated for being well organised and very informative. 
But opinions regarding the printed material vary from "too bulky" 
to "too scarce". It therefore seems advisable for the Commission 
to analyse further who are the recipients of the information and 
what measures they are expected to take after having been 
informed. It is very important that people are well informed and 
that the information is at the right level. 
2.2.13. Before the advent of BEP and BAP, biotechnology in Europe was 
fragmented and dealt with solely on a national basis. Now an 
infrastructure has been established with nodes of excellence in 
many areas. Me have seen clear evidence that in plant molecular 
genetics, Europe is considered to be competitive and even ahead 
of the United States. There is a growing supply of trained 
people with skills appropriate for the further development of 
biotechnology. Many of them have been trained in Europe. The US 
is no longer regarded as the ultimate training site. 
32 2.2.14 However, much remains to be done before biotechnology can have 
its full impact on European society. For the future it seems 
necessary to concentrate on issues of importance to Europe and to 
set out verifiable goals. Harmonisation of legislation, 
information network systems and culture collections, safety 
assessment, and information to the public based on scientific 
facts are all areas where increased activity and coordinated 
action on a European level is desirable. 
2.3. The views of the contractors 
2.3.1. During our missions, we met some 84 contractors or their 
representatives, who were responsible for a total of 27 out of 
105 BEP contracts (26%) and 78 out of 274 BAP contracts (28%). 
They were taken from those who responded positively to the 
panel's original invitation to some 176 contractors : these were 
chosen purely on a geographical basis as being located near to 
the cities that panel members could conveniently visit in the 
time available. 
2.3.2. The interviews lasted, on average, about 45 minutes and normally 
began with a short presentation by the contractor of the research 
work and the results obtained. Our conclusions on the work 
carried out in the different sectors are given in Annex 3. In 
the paragraphs below we give a summary of the contractors' views 
on a number of organizational issues. 
2.3.3. One question sought to determine whether the EC contract had 
affected the directions in which the contractor's group's 
research had gone. For four (5%) a new area had been started, 
for 18 (21%) it introduced a major change, and for 17 (20%) it 
made a modest but significant change. It thus appears that the 
EC programmes have caused some noticeable changes of direction 
for about half the contractors. 
33 2.3.4. There was usually a lot of discussion about trans-national 
cooperation. Although some contractors expressed scepticism 
about the genuineness of other trans-national links, none doubted 
the value of their own. In fact, the greatly increased volume 
and intensity of such collaborations was one of the most striking 
features to emerge. Thirty one respondents (37%) had much more 
positive attitudes and a further 35 (42%) were a bit better 
disposed to them. One contractor commented that because of 
competition between researchers within Member States, trans-
national cooperation was in some ways easier. 
2.3.5. Attitudes to trans-national links between industrial firms and 
research centres/universities were less easy to determine. Links 
seemed to remain largely with firms in the same Member State, but 
9 contractors (11%) now had much more positive attitudes to 
trans-national associations, and 21 (25%) were a bit more 
positive. 
2.3.6. Community support for research is normally limited to 50% of the 
costs, and one question asked who provided the remainder of the 
money. The overwhelming answer was government; 64 or 76% 
mentioned support by national or regional organisations. Some 27 
(32%) referred to the receipt of industrial support, quite often 
through the secondment of an industrial scientist to work in a 
university or through contract research placed with the group, 
(In France and Italy, because of employment legislation, EC money 
was used only for equipment, consumables, and travel, not for 
personnel; elsewhere each contract typically supported one post-
doc and a student or technician.) 
2.3.7. A later question concerned the means whereby the research work 
supported by the EC might be exploited commercially. The 
principal route (where one was specifically identified) was 
through contract research (18, or 21% mentioned this); patenting 
and/or licensing would be undertaken by 11, or 13%. Six 
34 2.3.8. 
contractors referred to movements of personnel, such as industry 
hiring a scientist from the project or paying for a fello«. One 
of the contractors had set up his own firm to exploit his 
discoveries. 
Finally, contractors «ere asked to comment on the way the 
Commission had administered the programme. Some of them gave 
ratings on five aspects, and the table shows the percentages of 
responses in different categories: 
ra11 f ,
 Excellent Good Fair Poor Abysmal No rating 
Call for proposals 2 11 4 17 , lï 
Selection process 4 8 6 2 0 Rn 
Contract negotiation 0 12 4 14 1 !¡ 
Progress monitoring 11 32 2 5 
Dissemination of results 12 13 2 2 
0 50 
1 70 
2.3.9.  As the table shows, the main areas to be criticised were the call 
for proposals and the contract negotiations. Major complaints 
«ere the short notice provided and that the application procedure 
was cumbersome, especially in view of the small size of the 
contracts. Several contractors felt that there should have been 
clearly-defined goals but one took the opposite view and 
suggested that there should be encouragement for work that might 
lead to unexpected results. The problems with contract 
negotiation almost all involved the long time required, although 
in some countries there were problems about the ownership of 
equipment only part of whose cost had been met by the Commission. 
On the other hand, the EC money was flexible and could be used 
for different purposes if needs changed during the course of the 
work. 
2.3.10. The programme managers were clearly highly regarded, alike for 
their very helpful individual visits to laboratories as for their 
organization of sectoral meetings. Time and again contractors 
said how useful these had been, how they had led to good trans-
national contacts, and how they had thereby helped the research. 
35 The enthusiasm and professional abilities of the Commission 
officials were repeatedly mentioned. 
2.4. The views of industry 
2.4.1. During our missions we were able to talk to representatives of 16 
industrial firms, 5 of whom were BAP contractors. This 
represented a disappointingly small sample of the 54 firms to 
whom we wrote originally. Almost half the firms did not even 
reply. Ue are forced to conclude that the Community's 
biotechnology research programmes are of marginal industrial 
interest, despite the number of firms who originally wrote 
"expressions of interest" in particular projects (some 112). 
2.4.2. Subsequently we sent a written questionnaire to some 210 firms, 
most of whom had not been involved in the "expressions of 
interest" exercise. Responses were received from 77 (by 3 
August)*, and they are reported in paragraphs 2.4.4. - 2.4.10. 
below. 
2.4.3. Among the 16 industrial firms seen personally, the sectors 
covered were plant breeding (6), pharmaceuticals (4), 
agricultural inputs and food and drink (3 each), and animal 
health and fine chemicals (2 each). The prevailing view 
(expressed by 8) was firmly that EC research programmes should be 
driven by science, not by industry, although the latter could 
usefully participate through the secondment of staff to research 
institutes. The existing contracts were seen as much too small 
and too scattered to have an impact or solve problems, but at 
least they brought scientists from different countries together 
and allowed an outside view on the state of European science. 
This Annex was completed later than the Summary Report and 
consequently includes more responses. 
36 Safety assessment was seen as an important future topic and was 
mentioned spontaneously by 6 firms. The Commission's training 
programme's value uas endorsed (also mentioned by 6 firms); there 
was, however, a particular need for more people to be trained in 
plant physiology and cell biology. 
2.4.4. The written questionnaire was sent to firms active in 
biotechnology research in the six Member States with panel 
members, who furnished the lists. The numbers sent out and 
returned (by 3 August) were as follows: 
Sent puţ Returned 
D 28 15 54% 
F
 
3
8 16 42% 
G
R
 
2 1 50% 
I 40 4 10% 
NL 45 24 53% 
UK 57 17 30% 
210 77 37% 
Some 55% of the respondents were independent; most of the rest 
were subsidiaries of larger concerns. 
2.4.5. The initial questions sought to establish the size of the 
respondent firms, in terms of their overall numbers of staff, and 
numbers of professional research staff. The results were as 
follows: 
Size of firm: payroll N 
1 - 200 "small" 
201 - 500 "medium-sized" 
501 - 5,000 
5,001 - 50,000 "large" 
> 50,000 "very large" 
Size of firm: research staff 
0 
I - 10 
II - 100 
101 - 1,000 
> 1,000 
No answer 
35 
3 
21 
13 
5 
Ν 
1 
35 
29 
9 
0 
3 
45% 
4% 
27% 
17% 
6% 
1% 
45% 
38% 
12% 
-
4% 
37 The following sectors of biotechnology business were represented 
with some firms being active in several: 
- Fine or specialty chemicals 31 40% 
- Human pharmaceuticals 26 34% 
- Diagnostic kits 17 22% 
- Agricultural inputs 16 21% 
- Seeds & plants 15 19% 
- Bulk chemicals 14 18% 
- Food and drink 12 16% 
- Ufaste treatment 11 14% 
- Equipment and instruments 10 13% 
- Animal husbandry 8 10% 
- Other 16 21% 
2.4.6. The first substantive group of questions asked about the firms
1 
awareness of EC biotechnology programmes and whether they 
received regular literature from the Commission. 30, or 39%, 
were adequately informed, but 44% would have liked more 
information and 13% had not heard of the programmes. Only 25, or 
32%, were on a mailing list. However 28, or 36%, had read 
scientific papers deriving from BEP and BAP, and 16, or 21%, had 
found them useful. 
2.4.7. The next questions asked about "expressions of interest". 34, or 
44%, had been invited to make one, and of these most (74%) had 
accepted. The reasons for declining indued difficulties in 
finding another industrial partner, reasons of confidentiality, 
and concern that the application process was too slow and 
cumbersome. Rather fewer had been asked to attend a seminar or 
workshop by the Commission, only 17, or 22%, admitted to this, 
though all but two went and found the proceedings very or fairly 
useful. 
2.4.8. Questioning then turned to the preparation for BRIDGE. A 
definite pattern was clear, with only 11, or 14%, having played 
38 any part, whereas 46 (60%) would have wished to have been 
consulted and 40 (52%) wished to play a role in the selection of 
research contractors. 
2.4.9. As for the content of BRIDGE, there were mixed feelings about 
whether industry should be required to participate financially. 
42, or 55%, said they should, but 9 said no. Over half the 
respondents (58%) felt that the initiative for proposals could 
come equally well from research institutions or industry, but 10 
(13%) felt that industry should be in the lead. 
2.4.10. Despite the desire of industry to see a more industrial face to 
BRIDGE than BAP, there was no great willingness to contribute 
themselves. Only 13 (17%) said they would be willing to 
contribute in cash or in kind, but 40 (52%) were quite happy to 
continue with the present system of "expressions of interest", to 
be followed by receipt of new publications and invitations to 
meetings. Only 7, or 9%, did not wish to play any part in 
BRIDGE. 
39 40 ANNEX 3 
ASSESSMENT OF THE RESEARCH SUB-PROGRAMMES 
3.1. Summary of activities 
3.1.1. Under the first programme, BEP, there were five sectors for 
research, and a total of 103
1 contracts were let, as follows : 
1. Second generation bioreactors for detoxification and for 
industrial applications including agro-food : 18 
2. Improved production of substances for animal husbandry «nri 
agro-food industries : 29 
3. Upgrading of plant products, particularly ligno-cellulose; π 
4. Improvement .. of plants and microorganisms .. important .. in. 
agriculture : 54 
5. Development of methods for detecting contamination and for the 
assessment of possible risks. : 2 
The total commitment for research contracts was some 10.4 Mecu 
out of the total programme budget (including the revision) of 15 
Mecu. Thus the average contract was about 101 kecu. 
3.1.2. Under the second programme, BAP, there were two sub-programmes, 
of which the first comprised 'contextual measures* and the 
second, six sectors of 'basic biotechnology'. There was a 
deliberate attempt to group different contractors into projects, 
with an average of 2.8 laboratories per project, virtually always 
with at least two Member States involved. The numbers of 
contracts and projects per sector were as follows : 
The numbers in each sector are taken from the BEP catalogue of 
contracts, and involve some double-counting (they total 114). 
41 Subprogratnme I : 
Bio-informatics 
Biotic materials 
Subprogramme II : 
Enzyme engineering 
Plant cells 
Micro-organisms 
Risk assessment 
Animal cells 
In vitro toxicity 
Projects 
Contextual measures 
12 
5 
Basic biotechnology 
17 
23 
13 
3 
16 
6 
Contracts 
42 
13 
45 
64 
35 
7 
40 
16 
95 262 
The total commitment for research contracts was some 37.7 Mecu 
out of the total programme budget of 55 Mecu (less 5.5 Mecu for 
the concertation activities), so the average contract value was 
about 144 kecu. In practice, the contracts were typically for 
three years, so contractors each received about 50 kecu per year. 
3.1.3. It has been difficult for us to assess the effectiveness and 
impact of each sector as it consists of so many small contracts. 
As section 2.3. showed, we talked to many contractors, but they 
still represented a fairly small sample of the whole. The 
reports and papers are similarly too numerous to allow other than 
a rather cursory examination. Ue have set out below our comments 
on each of the sectors in turn, and have tried to assess : 
1. the quality of the scientific work and of the groups involved; 
2. whether there have been major scientific breakthroughs and 
bottlenecks removed; 
3. what the major constraints on research in the sector are (if 
any); 
4. the extent of transnationality of the projects or "European 
added value" (this really only applies to BAP); 
42 5. the extent and durability of links between industry and 
academic or government laboratories; 
6. how well the Commission staff monitored the work; 
7. the arrangements made by the Commission for dissemination and 
exploitation of the research; 
8. what the future goals for the sector should be. 
3.1.4. The sections below follow the order of the BAP sectors, and 
include comments on work carried out under BEP as well, where 
appropriate. A number of contractors received support under both 
programmes, and their work under BAP was often a continuation of 
work begun under BEP. Despite the fact that the BEP programme 
nominally ended in March 1986, money is still being spent on the 
support of BEP research contracts, some research is still taking 
place, and scientific papers can be expected to be produced over 
the next year or two. On the other hand, results from BAP are 
already beginning to occur, and BAP papers are being published. 
In practice, therefore, the two programmes overlap to a great 
extent, and it is not possible to draw a clear distinction 
between them for purposes of evaluation. 
3.2. Contextual measures : bio-informatics 
3.2.1. Several distinct activities can be recognised in this section of 
the sub-programme on contextual measures. In its management, the 
Commission has quite properly separated those projects relating 
to software for problem engineering and for bioreactor control, 
and has managed them as part of the relevant areas within the 
basic biotechnology sub-programme. 
3.2.2. The contextual projects themselves consist of three in data 
capture, two in databank creation, and one for software to 
provide access to protein sequence databases. The small number 
and size of most of the projects makes it most unlikely that the 
43 sub-programme ui11 reshape the European market for laboratory 
instrumentation for the life sciences, though at least one of 
these projects is highly novel and has an industrial contractor 
within it. 
3.2.3. The most ambitious project has been to develop a European network 
of microbial culture collections (MINE). In contrast with the 
USA, the European life scientist is faced with a considerable 
number of well-established, well-funded, highly competent 
microbial culture collections, distributed across the countries 
of the Community. Amongst these collections, on-line 
computerised searching is still the exception rather than the 
rule. 
3.2.4. The objective of the MINE project was to harmonise the 
organisational methodologies of one or more large microbial 
culture collections in each of five Community countries, to use 
that as the basis for computerisation of each collection, and 
then integrate these national "nodes" into a European network. 
3.2.5. The project has achieved the establishment of common hardware and 
common (or at least compatible) software and the first exchange 
of data between some of the national collections. However, it is 
evident that the project has progressed much more slowly than it 
should have, partly because only now, some two years after the 
initial contracts were let, has an effective project management 
structure begun to emerge. It has also become evident to the 
Commission and the contractors that a distributed network will be 
impractical, especially when additional European collections are 
added in the future. The contractors have proposed an extension 
to the project, to allow the establishment of a centralised 
database, into which the data in all the participating European 
culture collections would be entered. One example of such a 
centralised database is that developed in the UK for its various 
national culture collections. 
44 3.2.6. Ue believe that the Commission should use the extension of the 
BAP programme in part to fund this extension of the MINE project, 
so as to achieve the initial objective by 1991. It should ensure 
that a project manager is appointed and that, in parallel with 
the development of a centralised database to provide an on-line 
search capability, its long term financing is agreed with the 
contractors, to the same deadline. In subsequent projects, 
including those under BRIDGE, further European culture 
collections should be invited to join the centralised database, 
according to the needs established by consultation with European 
industrial and academic researchers. 
3.2.7. The preparations for an integrated, searchable database already 
made by the NINE project offer the opportunity for a system which 
would be in advance of any other system in the world in its size 
and accessibility. It should therefore be able to offer a 
significant advantage to European researchers, and greater demand 
on the contributory collections. In principle, this ought to 
provide the basis for a self-financing operation. 
3.2.8. The establishment of a European node protein sequence databank 
has progressed well. However, as noted later in our 
consideration of protein engineering, the overall resource so far 
committed to creating novel databanks and making them readily 
accessible has been sub-viable, and needs to be co-ordinated with 
the relevant part of the AIM programme (Advanced Informatics for 
Medicine). 
3.3. Contextual measures : collections of biotic materials 
3.3.1. Five projects were set up under BAP, one to improve the 
methodology of fungal preservation and the others to create 
collections of novel materials. 
45 3.3.2. Life science research has depended on and will always require 
physical preservation of life forms, from those which protect 
plant species from extinction to those which catalogue the 
genetic determinants (some as yet to be identified) of man's 
illnesses. In most of the projects supported by the Commission, 
it is encouraging that the more recent techniques for 
identification of and discrimination between species (restriction 
fragment length polymorphism, 2-dimensional gel electrophoresis, 
etc) are being systematically applied. 
3.3.3. The Commission programme appears to be achieving an added value 
by creating viable biotic collections from those which had 
previously been fragmented. However, the programme as a whole 
needs more vigorous action in making such collections available 
to on-line searching and in advertising their availability. 
3.3.4. The breadth of biotic materials available to industrial and 
academic researchers in Europe is not yet matched by its 
accessibility, nor by the apparent willingness of researchers to 
pay for access. CEFIC
2 has set out its objective for European 
industry in "Bio-informatics in Europe" (May 1987), and "The 
Approach of the Biotechnology Industry to BRIDGE" (November 
1987). The Commission should develop a strategy based on these 
objectives, through further discussion with industrial and 
academic researchers, and should explore means of speeding up 
further developments through industrial funding. 
3.4. Basic biotechnology : enzvme engineering / bioreactors 
3.4.1. Several of the projects are of considerable quality and 
industrial interest, notably those on computer modelling, 
microbial transformations of fatty acids, and the continuous 
3 Confédération Européenne des Fédérations de l'Industrie Chimique. 
46 synthesis of fine chemicals. Also of high quality, but of more 
academic interest, is the work on co-factor regeneration and 
retention. The transnational project of the groups of Compiègne, 
of Napoli, of the National Hellenic Research Foundation and of 
Hannover is potentially of interest to the oil industry. On the 
other hand, the bio-electric catalysis project is unlikely to be 
realistic on an industrial scale. The project on enzyme-loaded 
erythrocytes is somewhat futuristic with its combination of rDNA 
and cell technology. 
3.4.2. There have been no ma.ior breakthroughs reported so far, although 
all the projects have some potential to remove bottlenecks 
hampering industrial applications. 
3.4.3. Although the sector is of potential industrial interest, the very 
small size of contracts has deterred industry from making 
applications. Moreover many of the academic groups we saw seemed 
primarily concerned with open publication rather than with 
securing patent protection or working with industry on a 
proprietary basis. 
3.4.4. There was effective trans-national cooperation, involving seven 
Member States, but surprisingly Denmark was not among them 
despite its strength in biotransformations. 
3.4.5. There was only one industrial firm (Henkel) involved as a 
contractor under BAP. Despite the multitude of expressions of 
industrial interest, few firms participated actively in the work. 
However industrialists will probably take a more direct interest 
in the synthesis of fine chemicals project involving GBF, 
Braunschweig, the Fraunhofer Gesellschaft, Stuttgart, and the CNR 
in Milan. 
3.4.6. The research activities in this sector are well monitored and 
managed by the Commission officials. The Commission staff have 
47 been active in disseminating the results (e.g. through the BAP 
Progress Report 1987), and through sectoral meetings (Compiègne 
1986, Capri 1987). 
3.4.7. For the future, a prime goal is to transfer the academic 
research results to industry. There are potential applications 
of biocatalysts for biotransformations in bioreactors in the 
chemical and agricultural industries, and for waste water 
treatment. Genetically-modified biocatalysts should be explored, 
as should the use of biotransformations under extreme conditions 
of pH, temperature etc, and with inorganic solvents. There is 
also scope to develop optimised bioreactors, preferably 
integrated with downstream processes and involving the 
participation of equipment manufacturers. 
3.5. Basic biotechnology - plant cells 
3.5.1. As in the other sectors, there was intense competition for 
contracts and only about one in five proposals could be funded. 
The contractors included most of the best European groups working 
in the sector, who were also able to assist and encourage ones 
with less experience. Both BEP and BAP produced some notable 
scientific results, although it is not always possible to 
identify the specific role of Community support. 
3.5.2. The main achievements of the research in this sector have been a 
greater knowledge (the mechanism of regulation) and new tools 
(vectors), rather than products in the form of new plants. This 
was indeed the original intention, which was correctly specified 
some years back. Some particular results are worthy of note : 
- the identification and the cloning of the regulatory gene for 
the production of zein (a storage protein poor in lysine) in 
maize 
- the transfer and the expression of genes implicated in the 
48 regulation of nitrogen fixation from soybean to Lotus 
com i cu latus. 
3.5.3. The original scope for the sector, set out by the Council, 
covered five fields : 
1. Extension of developments in molecular biology to plants and 
microorganisms of importance to agriculture. 
2. Physiology and genetics of plants and micro-organisms. 
3. Technology of cell culture 
4. Breakdown of lignocellulose materials 
5. Risk assessment. 
Since the programmes' budgets were very much smaller than those 
originally requested by the Commission (15 Mecu instead of 26 for 
ΒΕΡ, 55 Mecu instead of 88.52 for BAP), with the agreement of the 
CGC, the full scope of the plans set out in the Council Decisions 
could not be covered. A major effort was made in molecular 
biology, but there have been few projects on cell culture or risk 
assessment. The physiological work was abandoned, and the ligno 
cellulose sub-sector was re-oriented. 
3.5.4. One of the most positive achievements of the work in this sector 
has been to develop, or even to establish, intensive 
collaboration between groups working in the same area. Wider 
links have been created in the context of the 11 European 
Laboratories Uithout Walls, ELWWs
3. This new development is an 
interesting initiative and it deserves further support. Some of 
3 - Fundamental aspects of plant cell regeneration. 
- Regulation of expression of nodulin genes. 
- Cell biotechnology for crop improvement. 
- Molecular biology of cereal seed proteins. 
- Mitochondrial molecular genetics in relation to crop improvement 
- Host pathogen interactions with fungi. 
- Molecular biology of phytopathogenic Erwiniae. 
- Plant hormone receptors. 
- Late symbiotic genes : construction of improved strains. 
- Pollen biotechnology. 
- Hairy root and auxin sensitivity. 
49 the ELUUs should receive stronger support through work on 
clearly-defined research projects which would be specifically 
supported by the Commission. 
3.5.5. Industry has not been ignoring the work and has shown (and 
continues to show) a lively interest. However the benefits are 
still too distant in time for firms to be prepared to participate 
financially in the research, and indeed only A of the contractors 
are industrial firms. Nevertheless the fact that a score of 
university groups working on BAP contracts have established links 
with industry shows that their partners are really interested in 
their work. 
3.5.6. The Commission staff have run the sector with exemplary efficacy 
and dynamism. The majority of the research groups have thereby 
been inspired to work yet more closely together. Because of the 
close attention they have paid to the work being carried out, the 
officials have managed to reorient the sub-programme on 
transformation of ligno cellulose products towards the study of 
cellulotic activities and pathogenic pectolytic agents such as 
Erwjnia, spp. 
3.5.7. In future, more thought should be given to the relationships 
between research workers and industrial firms. Ue consider that 
two ideas should inform such consideration. First, the pay-back 
time from research in this sector is very long. Second, the very 
survival of the European seed industry (and perhaps the 
independence of agriculture) depends on a commitment to long-term 
strategic research. This will lead eventually to the mastery and 
dissemination (as both seeds and plants) of a modified genome 
coding for improved agronomic traits or better grain properties. 
But most European seed firms are small and cannot afford to 
support such research work. It therefore falls to public 
authorities to provide the funds and to ensure that the results 
are well-disseminated. Ue think that in such an important sector 
50 it would be wrong to require industrial contributions to projects 
in BRIDGE. Industry can however help to define the objectives of 
the work and to select the contractors, and we think it should be 
encouraged to do both. 
3.5.8. We were disappointed that there was no call for proposals in cell 
physiology. It is of no use to master how to transfer genes to 
different plants and to know how to switch them on if one doesn't 
know where the new tools should be applied. Horeover it is very 
clear that the tools and the insights provided by molecular 
biology can make a big contribution to plant physiology. Thus 
BRIDGE projects should not merely be transnational but also 
multi-disciplinary. 
3.5.9. lie believe that the following should be the main priorities for 
future research objectives : 
1. The molecular foundations of cell physiology in plants, with 
the work being steered towards the mechanisms of cell 
regeneration (especially in monocots) and of gene regulation, 
(e.g. for the determination of plant responses to 
environmental stresses and pathogens, or for changes in the 
composition of the storage components which govern the plant's 
utility). 
2. Studies of interactions between plants and micro-organisms 
including means for their identification and the reactions of 
the micro-organisms to the plants. 
3. Assessment of the potential benefits and hazards from 
developments in this sector together with a programme to 
communicate the results to the public, to be managed by CUBE 
(see Annex 5, section 5.3.4.). 
We recommend that, to the extent that it is scientifically 
feasible, work should be focussed on six major species, including 
both monocots and dicots, that are important for European 
agriculture (especially cereals) rather than on model species, 
although the latter should be used as necessary. The priority 
51 roust be for the use of the tools that molecular biology has 
fashioned. 
3.5.10. Bearing in mind the praiseworthy work that Commission officials 
have done to identify the research groups in this sector in 
Europe, and to persuade them to work together, we do not consider 
that a formal "call for proposals" is the only way to proceed. 
It should be possible to specify several projects of strategic 
importance, to bring together the research groups who express 
interest in working on them, and to identify a project manager. 
His or her responsibility would be to coordinate the work and 
ensure that the various teams helped each other. For such 
strategic projects there should be composite progress reports. 
3.6. Basic biotechnology : micro-organisms important to industry 
3.6.1. The projects in the area of microbial species important to 
industry cover a very wide range. Some 35 different laboratories 
are involved in 13 groups, concerned overall with 9 major 
industrial species of bacteria, yeasts and fungi. In most of the 
13 groups the project has been concerned with a fairly well-
defined model for genetic manipulation of the particular 
organism. In practice, both the contractors and the 
administrators have found it difficult to develop much synergy 
between the 13 groups, although there is evidence that efforts 
towards this end will prove significant in the formulation of the 
industrial micro-organism component of the proposed BRIDGE 
programme. 
3.6.2. All the contractors interviewed were enthusiastic about the 
quality of the science produced by their fellow contractors, and 
compared it favourably with parallel work performed outside the 
community programmes. They were also enthusiastic about the 
benefits of collaboration, expressed in terms of complementary 
52 skills and materials and of exchange of personnel. 
3.6.3. The impact of the groups on the totality of European research on 
the genetic manipulation of industrial micro-organisms has 
however been constrained by the wide spread of the projects 
within a limited budget. Many of the leading research 
laboratories have not participated in BEP or BAP, though steps to 
begin to correct this imbalance have been taken by the Commission 
through meetings it has arranged in the "brain-storming" sessions 
that are leading up to the formulation of BRIDGE. 
3.6.4. The lactic acid bacteria project has made clear progress, and 
the work under BAP undoubtedly benefited from the precursor 
projects in BEP as well as from the transnational collaboration 
effected by the BAP programme itself. Industrially, the output 
can be seen both in the elucidation of phage susceptibility and 
resistance and in the development of vectors to effect expression 
and secretion of model proteins. 
3.6.5. While reasonable scientific progress has been made in many of the 
other projects, the small numbers working on any one organism has 
prevented any dramatic impact. Some of the organisms for which 
work has been supported reflect a level of industrial interest 
which was perhaps true of the late 70s/early 80s but has now been 
much reduced. 
3.6.6. Therefore, while it is evident that some European added value has 
been gained by the complementarities in project skills and 
materials, the programme as a whole has not drawn as effectively 
as it might have done on the full strength of European research. 
3.6.7. Possibly for this reason, the number of industrial companies that 
have participated either in the contracts or in the sectoral 
meetings has been relatively low, compared with those interested 
in the sectoral meetings on plant genetic manipulation. The 
53 results of some specific projects are being closely monitored by 
industry and very probably will be taken up and exploited by 
them. However, we consider it likely that much less than half 
the projects will lead to additional development expenditure by 
these companies and that that expenditure will therefore be less 
than that committed under this programme. 
3.6.8. All the contractors complimented the Commission on the care taken 
to implement each contract, and on its organization of meetings 
which were especially valued for being gatherings of specialists. 
Many noted that the programme manager had not visited individual 
laboratories very much after the initial period, but made this 
only a minor criticism in view of the· other benefits they had 
obtained. Some noted that the meetings involving all the 13 
groups were less useful, as there was less of communal interest 
to discuss. 
3.6.9. The Commission has been active since the second half of 1987 in 
promoting discussion within the programme and also with non-
contractors to formulate the equivalent programme under BRIDGE. 
Academic and industrial groups have identified a much narrower 
range of organisms on which to concentrate, and have recommended 
an emphasis on multi-disciplinary teams to tackle the control of 
gene stability, overproduction, and secretion through genetic 
manipulation, biochemistry and physiology. 
3.6.10 In the same way that the Commission has used its initial academic 
contractors to widen the discussion to include non-contractors, 
so also it needs to widen its range of industrial participants 
and collaborators. Through such initial collaborations we 
believe it should seek to advertise the value of its present and 
future programmes taking special account of small and medium-
sized enterprises which cannot devote much manpower to 
discovering such values for themselves. The number of model 
micro-organisms for multi-disciplinary projects needs to be 
54 reduced still further, to perhaps one major project. 
3.7. Basic biotechnology : risk assessment 
3.7.1. Ue consider that the quality of research in this sector is good. 
The most ambitious project seems to be that on the field release 
of genetically-manipulated baculoviruses. However no scientific 
breakthroughs have so far been reported. 
3.7.2. The number of contracts is very small (7) and does not reflect 
the degree of concern which, rightly or wrongly, exists in our 
society today with regard to the possible negative aspects of 
biotechnology. 
3.7.3. Nevertheless, the work appears to us to be suitably transnational 
in character. There was a successful meeting in Bayreuth in 
October 1987 with 41 participants, including two from industry 
and several representatives of Member State governments. 
3.7.4. The work is closely monitored by the programme managers, who have 
visited almost all the contractors. There are well-established 
means for the dissemination of the results, and we note with 
satisfaction that the Commission will be sponsoring a major 
seminar later this year, probably in Berlin. 
3.7.5. A major goal must be to expand the activity in this sector. Ue 
strongly endorse the plans, under the revision of BAP, to devote 
over 4.6 Mecu out of the 20 Mecu to additional work. The main 
emphasis will be on the environmental release aspect, for 
example, the fate and possible ecological and human health 
problems caused by transgenic organisms, as well as the possible 
transfer of genetic material between organisms. 
55 3.7.6. Although we regard such work as vital in order to demonstrate 
that new biotechnological products and processes are safe, we are 
concerned that the current title of the sector may give a 
misleading impression. Ue would prefer it to be called "safety 
assessment", see para 2.2.11. 
3·
8· Pesic biotechnology : animal husbandry and animal cell culture 
3.8.1. This sector comprises two sub-sectors, of which the former is 
much the larger with 13 projects as compared with only three in 
animal cell culture. Ue are impressed with the work in animal 
husbandry : the scientific quality is very good and there are a 
number of very promising developments although no major 
breakthroughs have been reported. One criticism is that most of 
the work is concerned with viruses and consequently there is a 
rather small community (only A groups) working on bacteria, not 
enough to form a critical mass. Similarly, in the animal cell 
culture sub-sector, the small number of contracts (only 10) has 
restricted the amount of mutual benefit arising from sectoral 
meetings like the one held at Seillac in May 1987. 
3.8.2. The transnationality of the work is one of the roost successful 
aspects, and some half dozen ELWWs are under way (cf. para 
3.5.4). Two meetings were supported in 1987, both in Salamanca : 
one was a sectoral one on genetic engineering and the other was 
an independent one on African swine fever and pig immunology. 
Both were very successful, although the latter would have 
benefited from the active participation of DG VI, whose own 
research programme includes African swine fever. 
3.8.3. Both sub-sectors are developing good links with industry, and 
there are three industrial contractors (Solvay and Wellcome; 
Bertin). Ue noticed, however, that the more successful the 
research in animal husbandry, the less industry seemed interested 
56 to collaborate. In animal cell culture the work is largely pre-
competitive. 
3.8.4. The programme managers have been active in monitoring the work, 
and have visited most of the contractors. Apart from the 
reservation in para 3.8.2. above, the means provided for the 
dissemination of the research results seem to us to be 
appropriate. Me note with approval that links are being formed 
between groups involved in animal cell culture and those 
concerned with bioreactors and with in vitro toxicology, and that 
a joint meeting is being planned in Nancy towards the end of 
1988. 
3.8.5. Future research in animal husbandry should continue to 
concentrate on the two themes established for BAP, namely 
production of vaccines and interspecific gene transfer. In 
addition, it is important to support at a precompetitive level 
the development of modern diagnostic procedures in animal 
husbandry (e.g. for hormones, viruses, other micro-organisms and 
parasites). 
3.8.6. Me consider that animal cell cultures will be used increasingly 
to generate novel products for human and animal health. Animal 
cells (both vertebrate and insect) have a number of advantages 
over bacteria and yeasts, notably the capacity to bring about 
certain post-transcriptional enzymatic reactions such as 
glycosylation. We consider it desirable for this sub-sector to 
be continued and expanded, and to be linked to the sector on 
industrial micro-organisms. 
3.9. Basic biotechnology : in vitro toxicity 
3.9.1. There are six projects in this sector and their quality is good. 
Two of them are especially noteworthy, namely the one on altered 
57 immune gene expression, and that on in vitro screening for 
anticonvulsant teratogenesis in neural primary cultures and cell 
lines. The work on a new method of immunotoxicological 
screening strikes us as being a real breakthrough. 
3.9.2. Once again, the major constraint is the small number of contracts 
(16) in relation to the diversity of the subject. Given the 
limited budget, it would have been better to have concentrated on 
work that was likely to lead to improvements in basic knowledge, 
and to have excluded the more medically-oriented work on specific 
organs (skin, kidney, pituitary). 
3.9.3. The work has led to good transnational cooperation, although it 
is strange that none of the 16 contractors is in the Netherlands 
whereas five are in the UK. One ELHW has been established, based 
on the Centre Paul Broca in Paris and BIBRA* in Carshalton, UK. 
3.9.4. For exploitation of the work, it is necessary to involve both 
industry and national governments, and this is occurring. Skin 
models are now commercially available for medical use. Although 
there are no commercial firms among the contractors, BIBRA is a 
private-sector research association serving both industry and 
government, and so the new immuno-toxicological screening method 
is likely to find rapid application. 
3.9.5. The Commission's programme manager monitors the work closely. 
The results are well disseminated, both within the sector and to 
the scientific world outside. Meetings, like the one held in Bad 
Irsee, near Munich, are of major importance for the purpose. 
3.9.6. Me should stress that this sector not only exploits the new 
developments in biotechnology, but also can contribute new 
insights that will be of value both within the sector and to 
The British Industrial Biological Research Association. 
58 others. Thus we believe that future research should concentrate 
on tuo main lines. First, basic biomolecular research that is 
aimed primarily at the modulation of genome expression and cell 
differentiation by potentially toxic chemicals and drugs should 
be pursued. Second, novel test methods should be developed to 
identify possible undesirable effects on human health of neu 
biotechnological products such as peptides and proteins. But as 
we noted above (section 3.9.2.), we consider that any organ-
specific work should be undertaken within the medical and health 
programme. 
3.10 Protein engineering 
3.10.1 This is a relatively recent sector with five projects activated 
in the second half of 1986 and four activated in the first half 
of 1987. However, some evaluation is already possible. The 
scientific quality of the teams involved, and of the projects 
themselves, is high. The programme includes most of the best 
European groups with heavy representation of the countries with a 
strong tradition in the field (D, F, UK), and some representation 
from high quality groups from Mediterranean countries (GR, I, P). 
The transnationality and multilaboratory aspects are very good. 
3.10.2 This sector is markedly multidisciplinary, requiring inputs from 
X-ray and other protein structure determination procedures, 
modelling and structure prediction methods, classical enzymology 
and genetic engineering. The Commission staff has recognized and 
properly insisted on the multidisciplinary nature of the sector 
which, together with the high quality and multinationality of the 
groups engaged, augurs well for the projects. It should be noted 
that in this sector a multidisciplinary team focussed on the same 
project cannot easily be assembled even in the most advanced 
European countries. This points to the real necessity of 
transnational collaboration. 
59 3.10.3 The sector has important industrial applications. Two industrial 
laboratories are involved in the programme, but the value to 
industry really lies elsewhere : in the training of high quality 
specialists in the academic laboratories supported by the 
programme, and in the interactions possible though BAP-associated 
workshops such as the one held at Capri last year. Major 
industrial firms in Europe are building in-house groups in 
protein engineering, with resources far exceeding those provided 
by BAP and with guaranteed confidentiality. Thus, industrial 
interaction with the academic groups participating in this 
programme is a reasonable goal, e.g. through secondment of staff 
and active participation in meetings, rather than direct 
involvement of industry as contractors or as suppliers of funds. 
3.10.4 Europe has substantial strengths in this sector, although the 
number of specialists in some key fields (such as X-ray 
crystallography) is not large world-wide, and Europe is faced 
with increasingly strong competition from the US (in part because 
of major financial support by the Howard Hughes Medical 
Institute). It is important for Europe to maintain and 
consolidate its position, and support of research and training in 
protein engineering should therefore remain of high priority in 
BRIDGE. Finally, the sector overlaps with and is dependent on 
bio-informatics and other contextual measures. A number of 
projects in the latter sectors are of very high quality and 
represent a valuable input to the protein engineering sector. 
3.11 Genome studies (mapping and sequencing) 
3.11.1 This is a sector that has not been identified in past programmes. 
However, we consider that it merits separate discussion, since it 
encompasses projects planned for the BAP extension and for 
BRIDGE, and since it exemplifies some of the potential but also 
the limitations of the European response to the biotechnology 
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3.11.2 Recent advances in molecular biology and genetics (including 
developments in DNA sequencing and mapping procedures) have now 
made it feasible to envisage a complete knowledge of the complex 
genomes of higher organisms at the chemical level. This is 
symbolized by (but by no means limited to) the proposal for 
obtaining the complete sequence of the human genome (3x10" base 
pairs of DNA). That proposal was acrimoniously debated in the 
scientific community during late 1986 and early 1987, the 
acrimony largely generated by the fear that such a "big science" 
project would drain scarce resources from ongoing "small science" 
programmes. Remarkably, over the last year consensus has 
crystallized on the desirability of genome studies, not only on 
the human genome but also on selected model systems (such as 
bacteria, yeast, nematodes, Drosophila and the mouse). This 
development was partly stimulated by the deliberations and 
favorable conclusions of a National Academy of Science/National 
Research Council Committee in the US, and by the focus on genome 
studies in the Human Frontier Programme proposed by Japan. It is 
important to remember that key approaches to genomic studies were 
Pioneered in part in Europe (e.g. DNA sequencing by Sanger; 
construction of complete physical maps by Sulston). 
3.11.3 The underlying justification for a major initiative in this new 
sector is its importance both for basic biological knowledge and 
for applications in the fields of human health, agriculture and 
industry. For example, the detailed characterization of the 
human genome, with the resulting identification of a wealth of 
medically important genes and the generation of probes for 
detecting abnormalities in these genes, can be justifiably 
considered an investment in preventive medicine. Similarly, 
genomic mapping of plant and animal species of economic 
importance will be valuable for agriculture and pest control. 
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US response. Less than a year ago, the National Institutes of 
Health (NIH) committed $ 17.2 million for a year, which are 
being assigned to peer-reviewed grants and will be fully 
disbursed by the end of September 1988; increased funding is 
expected for the next and subsequent years, and the Nobel 
laureate J. Watson is being recruited to oversee this sector as 
an Associate Director of NIH. Furthermore, the Department of 
Energy is initiating major activities though its National 
laboratories (e.g. Los Alamos, Livermore), and additional major 
funding is expected from the Howard Hughes Institute and other 
non-governmental sources. 
3.11.5 An important European initiative in this field is the plan to 
sequence part of the yeast (Saccharomvcps cerevisiae) genome, in 
coordination with American, Japanese and other teams that will be 
pursuing parallel studies. In the BAP second phase, 2.4 Mecu for 
2 years are earmarked for this purpose, and a total of 10 Mecu 
are envisaged for scaling up the effort within BRIDGE. In 
addition, 2 Mecu are earmarked for sequencing the Bacillus. 
subtilis genome, and smaller amounts will fund the development of 
instruments and other contextual measures. 
3.11.6 In other EC programmes a start has been made in genome studies 
under the Stimulation Programme (Drosophila. 0.7 Mecu over 5 
years) and it is expected that 15 Mecu over 3 years will be made 
available for the human genome sequencing project through the 
medical research programme. Uhile these developments are 
encouraging, we note that the projected level of support is 
significantly lower than in the US, and that actual funding is 
mostly lagging behind the US by nearly one year. At the moment 
no plans have been made for similar work on species of 
agricultural importance (plants, insect pests). 
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informatics; a proposed 10 Mecu allotment for DNA-related work 
under the AIM programme (Advanced Informatics for Medicine; DG 
XIII) has been unfortunately eliminated by the planning group of 
that programme, which did not include experts in genetics. Ue 
must stress that for many uses of information technology in 
biotechnology, Europe risks becoming totally dependent on the 
USA. The limitations of the European initiative in genome 
studies may reflect the generally low level of funding for 
research in the life sciences, and slow and diffuse 
administrative procedures, which we discuss elsewhere in this 
report. 
3.12. Concluding remarks 
3.12.1. Ue have noted in several sectors the need for large scale 
projects, which would use the advantage of the European scale to 
make the maximum impact on major bottlenecks. Such projects 
would comprise multi-disciplinary teams of the necessary critical 
mass. Ue have also noted that the current system, of an open 
call for proposals, is not the only way to proceed (3.5.10) 
3.12.2. Ue therefore recommend that for each such large scale project 
the Commission should appoint a project manager who, in close 
cooperation with them, should organise a framework for the 
project for use in inviting applications, which would then be 
judged both on scientific merit and on relevance to the pre-set 
goals. 
3.12.3. Ue also noted earlier (2.2.6) that the small size of contracts 
offered under BEP and BAP (approximately 50,000 ecu/yr) was one 
of the factors that inhibited the participation of industry, and 
of some major academic laboratories. Ue therefore recommend that 
a flexibility should be introduced to allow some contracts to 
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scientists, postdocs, technicians,etc). This would imply some 
contracts of up to 200,000 ecu/year, assuming a continuing 
requirement by the Commission that contractors undertake 50% of 
project costs. Such contracts would often be within the context 
of the above large-scale projects which are envisaged as having 
an overall cost to the Commission of 1/2 million ecu/year or 
more. 
3.12.4. Ue believe it would be advisable in the future to plan for a 
degree of continuity for ELUUs and also to introduce some 
flexibility into Commission programmes, by instituting some kind 
of rolling mechanism into the calls for proposals. This could be 
done, for example, by staggering the periods of awards, and by 
repeating periodically the call for proposals, especially in the 
science-driven part of the research programmes. 
3.12.5. Such a flexibility would permit the pursuit of new ideas or new 
developments in the various sectors, and would also allow 
recruitment of further laboratories either as they are 
established or as they become more attuned to the needs of the 
programmes. 
3.12.6. It is also desirable to continue the process evolved during the 
BEP and BAP programmes to increase the scientific cohesion of the 
Community. In particular, special efforts should be made to seek 
the full participation of competent laboratories and scientists 
from less-developed regions of the Community. Such a special 
effort should certainly not involve quotas or the lowering of 
scientific standards. Instead it should focus on increasing the 
awareness and relevance of the programmes through means such as : 
- Assisting national authorities in searching out and fully 
informing laboratories in these regions about the available 
possibilities, including those arising from potentially 
complementary proposals being put together by laboratories in 
64 more developed regions. 
■ Making more frequent calls for proposals, as suggested in 
3.12.4., thus reducing the significance of disparities in 
access to information. 
To the extent that this is scientifically tenable, encouraging 
application of research to targets relevant to the less-
developed regions (e.g. Mediterranean crops). 
Encouraging the holding of sectoral and other «orkshops in 
less-developed regions and otherwise enhancing the contacts of 
young scientists from these regions with scientists from more-
developed parts of the Community. 
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ANNEX 4 
ASSESSMENT OF THE TRAINING ACTIVITIES 
4.
1. Summary of activities 
4.1.1. Fellowships have been awarded to 'young' scientists since 1983 
under both BEP and BAP to provide advanced training in a number 
of disciplines within biotechnology in good-class laboratories in 
another Member State. Under BEP, the fellowships were mostly 
'senior' ones for scientists with several publications already to 
their name. The fellows were paid a monthly stipend (the current 
rate is about 1711 ecu/month) and their host lab received a bench 
fee of 10,000 ecu/year. Under BAP, the emphasis has been shifted 
towards younger scientists, both new PhDs and doctoral students· 
they receive about 1369 ecu/month but no bench fee is paid. 
The total numbers of fellows and the financial allocations to 
date (May 1988) have been as follows : 
Senior Junior Total Commitment, Mecu 
BEP 72 5 77 3.2 
BAP 59 130 189
1 2.5 
A total commitment of 5 Mecu under BAP is planned for the 
training programme. 
Applications can be submitted at any time; they are selected for 
funding following quarterly meetings of the CGC on the basis of 
written evidence from the fellow, his/her previous supervisor and 
potential host. Most fellowships are for one year initially but 
a fair number of extensions for a second year are granted. 
4.1.4. During BEP, there were 222 applications so the chance of success 
was about 35%. So far under BAP there have been 369 applications 
and the success rate has risen to 51 %. The most common ground 
for rejection appears to be that the training programme proposed 
4.1.3. 
1 A further 43 fellows have been selected but are not yet in post. 
67 is not relevant to the aims of the BAP. 
4.2. Conclusions 
4.2.1. We regard the training element of the biotechnology research 
programmes as having been a success. The reports (see 4.4, 4.5, 
4.6) are very favourable : the fellows seem to be well-
qualified, work hard, and bring a fresh approach to their host 
laboratory. Horeover, the fellowships are mostly instrumental in 
fostering continuing trans-national collaboration, and have 
played a significant role in enhancing subsequent job 
opportunities for the fellows. 
4.2.2. Ue have seen the results of a survey of some 42 fellows and 57 
supervisors conducted by postal questionnaire in December 1987 by 
the programme managers. These largely confirm our own findings, 
based on personal interviews. The quality of the training and 
the standard of the host laboratories were regarded as very good 
in both surveys, although we doubt that the predominantly young 
fellows are really able to judge the latter because of their lack 
of standards for comparison. 
4.2.3. Despite these laudatory comments, there are some criticisms. On 
the administrative side, the procedure, although reasonably 
efficient, is very impersonal. There have been some difficulties 
with initial payments - one-sixth of the fellows complained about 
this. For most junior fellows, one year is insufficient to 
generate significant research results which they need in order to 
obtain a job afterwards. 
4.2.4. The level of stipend seems to us to be on the generous side : in 
some countries junior fellows are paid more than established 
scientists of the host laboratory. On the other hand, the lack 
of bench fees for these junior fellows is clearly a major source 
68 of complaint in many laboratories, especially university ones, 
and may cause some resentment, and a lack of feeling of 
independence for the fellow. 
4.2.5. A further problem is the lack of money for travel by the fellows 
to symposia and workshops, and to visit other laboratories in 
their host country. We feel that as a consequence many fellows 
do not obtain sufficient professional contacts in, or personal 
knowledge of, their host country. 
4.2.6. The points in the above three paragraphs were also made by the 
respondents to the Commission's postal survey, but they came 
across quite vividly in some of our interviews. Our conclusion 
is that a more positive approach to management of the fellowship 
programme must be made, including better marketing of the 
programme, and the promotion of closer contacts for the fellows 
with the Commission, and with other fellows in the same host 
country. 
4.3. Recommendations 
4.3.1. The training programme should be continued under BRIDGE and 
should be expanded to absorb about 15% of the budget (cf. 9% 
under BAP, 21% under BEP). This would provide for some 50 
fellowships per year under the revised conditions we recommend 
below. The objective of the fellowships should be to provide 
training in disciplines currently in critical supply, either 
locally or throughout the Community. 
4.3.2. The programme should be much more vigorously promoted, and should 
be managed by at least one full-time professional staff member-
plus administrative support. An appropriate target would be to 
attract at least four candidates for each fellowship. 
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Brussels for short-listed applicants, and the opportunity should 
be taken to provide candidates with briefing about the Community, 
and the biotechnology and other related research programmes. 
4.3.4. The Commission should provide detailed briefing material for both 
the fellow and his/her supervisor explaining what is expected of 
each, and giving up-to-date information on administrative matters 
for each Member State (e.g. liability to income tax, payments for 
health insurance, arrangements for annual leave and sick leave). 
4.3.5. The total payments to the fellow should be at the current levels, 
but 10% of the monthly stipend should be withheld and used to pay 
travel costs and a daily allowance for an approved programme of 
travel and visits to other laboratories in the host country 
totalling about two weeks per year of the fellowship duration. 
The stipend should be paid monthly in advance, and travel 
expenses should be paid promptly. 
4.3.6. Without precluding appropriate training activities of shorter 
duration, fellowships should normally be for two years, with the 
possibility of a third year in exceptional cases. The Commission 
should have the right to terminate a fellowship after one year if 
reports are unsatisfactory. 
4.3.7. Bench fees should be paid for junior fellows as well as for 
senior ones and should be at similar levels. The fees should be 
negotiated for each case individually and some account should be 
taken of the relative expense of the laboratory work in 
different topics. 
4.3.8. The responsible Commission official should visit or maintain 
contact in other ways with fellows during their tenure, and 
should encourage contacts between fellows in the same Member 
State or region through occasional meetings. 
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of all former fellows and their supervisors and keep in regular 
contact with them in order to provide news of biotechnology 
research initiatives and encourage former fellows to participate. 
This list should be published from time to time. 
4.3.10. We note with interest the support being given to the provision of 
intensive workshop and training courses in biotechnology in 
Greece, Portugal, and Spain. Ue should like to see this activity 
continue and expand. 
4-4. Analysis of questionnaires : BEP felloua f?9i 
4.4.1. There were originally 77 BEP fellows, and it was necessary first 
to obtain their current address from their former supervisors. 
Eventually 56 such addresses were obtained. During the missions, 
personal interviews lasting 20-30 minutes were held with 9 
fellows, and 20 others filled in a written questionnaire. 
Responses were therefore obtained from 29 or 38%. They were 
distributed by Member State as follows (numbers in parentheses 
correspond to the whole cohort): 
Β - 2 (9) GR - 1 (5) L - 0 (0) 
D - 3 (13) 1-4 (10) NL - 3 (7) 
DK - 2 (4) IRL - 2 (3) UK - 4 (8) 
F - 8 (18) 
The sample was therefore fairly good except that Belgium, 
Germany and Greece were under-represented. Spain and Portugal 
were not Member States at the time and so did not participate. 
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4.4.2. The distribution of the host-laboratories of the 29 BEP fellows 
compared with the total population was as follows : 
Β - 6 (11) GR - 0 (2) L - 0 (0) 
D - 5 (15) I - 0 (2) NL - 2 (3) 
DK - 2 (5) IRL - 0 (1) UK - 13 (27) 
F - 1 (11) 
The UK was therefore somewhat over-represented and France under-
represented . 
4.4.3. Of the 29 fellows, 21 were now living in their country of origin, 
and 2 had gone to the U.S. Six had stayed on in their host 
country after their fellowship. Of the total of 56 fellows who 
were traced, 18 no longer resided in their country of origin 
(32%, cf. 28% in the sample of respondents) including 7 out of 8 
from the UK. 
4.4.4. The fellows were on fellowship on average about 1 1/2 years, and 
had finished their tenure a mean of 2.4 years ago. They were 
thus able to reflect fairly well on the time they spent in 
another country. The principal advantages mentioned were 
72 contacts with other scientists (18), better scientific knowledge 
(13) and new techniques (13). There were personal advantages, 
too : 10 mentioned an improvement of their language, mostly 
English, and 7 enjoyed social and cultural contacts. 
4.4.5. Twelve found their fellowship better than they expected, but 5 
were disappointed. Problems included late payment of stipend or 
bench fee (5 mentions), a new language (3) and the lack of 
opportunity to go to scientific meetings (3). But these problems 
were generally out-weighed by the professional advantages of 
having trained in new techniques in a good laboratory, with 
possibilities for publications (25 out of 29) and continuing 
links with their supervisor (24 maintained these). 
4.4.6. The fellowship seems to have had a beneficial effect on future 
employment : 14 thought it had a major influence and a further 6 
that it was of some help. (Most of the rest had a job to which 
they returned.) It was also thought to have a significant long-
term career advantage by 18 out of the 29. 
4.4.7. Fellows mostly returned with better impressions of their host 
country and the Commission. On their host country, 10 considered 
it much better and 7 a bit better afterwards; only two thought it 
worse. The Commission was much better appreciated by 14 and 
somewhat better by a further 11, but 3 were disappointed - mainly 
because of slow or cumbersome administration. 
4-5. Analysis of questionnaires : BAP fellows (23) 
4.5.1. Twenty-three fellows were interviewed by groups of three panel 
members during their missions. Of these 18 were female and only 
5 male, a disproportion which is at variance with the overall 
ratio for BAP fellows of 2 females to 3 males. For 14 of the 
fellows, panel members also saw their supervisors. 
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Β - 1 (17) F - 6 (47) L - 0 (1) 
D - 3 (23) GR - 3 (20) NL - 0 (6) 
DK - 0 (2) 1-2 (24) Ρ - 1 (6) 
E - 5 (23) IRL - 2 (8) UK - 0 (12) 
(Numbers in parentheses are for all the BAP fellows.) The sample 
was 12%. 
Whole cohort 
BAP fellow distribution by Member State 
4.5.3. Three of the fellows were classified as 'senior', the other 20 
were 'junior', (cf. 59 and 130 for BAP as a whole) of whom 7 
were working towards a PhD degree. Most (14) had tenure for one 
year; 7 had received a second year's extension. Nearly all (19) 
had not previously lived or worked in another Member State. 
4.5.4. The main reasons for the fellows having applied were personal 
(primarily to learn English or to experience living elsewhere in 
the EC) and professional. 
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- their professors (8), notices or advertisements (6), and other 
fellows (4). Some had sought to work with their supervisor first 
and had then learned about the scheme from their host-laboratory. 
4.5.6. One question asked about the relative attractions of Europe and 
the USA to potential fellows. Hardly anyone would have 
preferred to go to the US; the award was considered at least as 
good as one for the US by 10 and, if anything, superior by 5. 
4.5.7. The stipend was regarded as about right by 10 out of the 23 and 
generous by 8. One said the money was not enough; the other four 
did not comment. However three fellows complained that their 
initial grant was late in arriving, and several suggested that 
the stipend should reflect the high cost of accommodation in 
certain large cities (notably London and Paris). 
4.5.8. As expected, there were problems for some in finding 
accommodation (mentioned by 6), coping with the language, and 
settling to living in another country. But most of the fellows 
settled easily and received quite a bit of help from their host 
laboratory. 
4.5.9. The host labs were well regarded by the fellows, 8 saying they 
were an improvement on those of their own country, and 7 at least 
as good. (Only one was less wel1-equipped.) The main advantages 
were seen as the high level of training (seen as excellent by 7 
and good by 9), the contact with other scientists through 
seminars, etc. (6 mentions) and good equipment (8 mentions). 
4.5.10. The fellowships have been reasonably successful in changing 
people's attitudes about Europe. Nine fellows now had much 
better views of their host country, and four a bit better; only 
two were less well disposed (because of the lack of sunshine in 
northern Europe and the cost of living). There were many 
75 positive remarks about the friendliness of the people of the 
host countries. But several fellows lacked for personal contacts 
and would have liked to meet other Community fellows in their 
host country for mutual support. 
4.5.11. The Commission, though regarded as a courteous and efficient 
source of support, was viewed as a rather remote and impersonal 
body. Only 3 now regarded it in a much better light, 10 a bit 
better, and 7 were unchanged - they had no feelings about it. 
4.5.12. As regards their future career, 13 fellows felt the fellowship 
would have a very positive effect and 2 a small effect; none felt 
it would be negative. Eight fellows expected to return to their 
country of origin and a futher eight might do so, but five 
thought it unlikely - mainly because of the lack of available 
jobs. 
4·
6- Analysis of questionnairps · Supervisors (21) 
4.6.1. The responses were again obtained through face-to-face 
interviews, averaging 20-25 minutes, with panel members during 
missions. A total of 21 supervisors were interviewed, who were 
responsible for some 25 fellows, one of whom had not yet taken up 
his post. They were distributed by Member State as follows : 
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(23
) GR - 0 (2) NL - 3 (20) 
D
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1 (3) I - 0 (3) Ρ - o (2) 
E ' °
 
(3
) IRL - 1 (5) UK - 7 (69) 
Numbers in parentheses show the total numbers of supervisors who 
have taken part in the BAP training programme. The sample was 
11 %. France was under-represented but Belgium was over-
represented. 
76 4.6.2. 
Whole cohort 
BAP Supervisor distribution by Member State 
The distribution of their BAP fellows 
nationality was as follows : 
Β - 2 (17) F - 8 (47) L 
D - 2 (23) GR - 3 (20) NL -
DK - 0 (2) 1-2 (24) Ρ 
E - 0 (23) IRL - 2 (8) UK -
(21 out of 25) by 
0 
1 
1 
0 
(1) 
(6) 
(6) 
(12) 
4.6.3. The majority (15) of the supervisors were initially approached by 
their prospective fellows directly; roost of the other contacts 
arose from a pre-existing link with the fellow's professor or 
supervisor in his/her country of origin. 
4.6.4. Two thirds of the supervisors said that the fellow had made or 
was making a very positive contribution to the laboratory, often 
more than would be expected from a host-country national because 
of different scientific approaches or contacts, and because many 
'A 
77 of the fellows worked extremely long hours. There were no 
adverse reports on fellows. 
4.6.5. The presence of the fellow involved extra costs for the host 
laboratory; one-third indicated a sum between 3,000 and 10,000 
ecu/year, and one-third said it cost them over 10,000 ecu/year. 
This money had to be found (in the absence of a bench fee paid by 
the Commission) by the laboratory, and was a considerable 
impediment for 8 supervisors, although 7 seemed able to manage 
without a bench fee (notably at the well-funded EMBL at 
Heidelberg.) 
4.6.6. Most of the supervisors expected publications to result from the 
fellowship (16); none said it was unlikely although the short 
tenure, normally only one year and in one case, six months, 
clearly made it difficult for a fellow to make a significant 
contribution in a new area. 
4.6.7. The supervisors were divided on whether the fellowship was likely 
to generate useful contacts in the fellow's country of origin. 
Four said yes, the fellowship was very helpful in this regard, 
and a further 7 thought it was quite helpful (some of these would 
have already had close contacts); 9 said it would not be useful. 
4.6.8. On relations with the Commission, 2 claimed a much better 
relationship and 4 that it was a bit better, but for 6 it was 
unchanged and for 3 a bit worse. The negative aspects were the 
lack of contact, poorly-designed literature, the absence of a 
bench fee, and the denial of a possibility of renewal of the 
fellowship. The limitation of fellowships to 12 months, at least 
initially, was criticised by eight supervisors : there was a 
clear consensus that two years was needed for young scientists 
(although one year might be enough for a senior scientist on a 
sabbatical). 
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more closely with industry; nine said it made no difference. 
None said there was any problem. 
4.6.10. On future prospects, 11 supervisors were happy to continue to 
receive EC fellows, but 9 said that the conditions would have to 
change, mainly through the provision of a bench fee or a longer 
period of tenure. 
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ASSESSMENT OF THE CONCERTATION ACTIVITIES 
5.1. The need for concertation in biotechnology 
5.1.1. CUBE, the Concertation Unit for Biotechnology in Europe, is in 
general responsible for concertation in the area of biotechnology 
and more specifically it is responsible for the concertation 
activity within BAP (Council Decision of 12 March 1985). Me 
therefore consider first the need and rationale for the 
concertation activity per se and then the particular 
institutional implementation that this activity has been given in 
CUBE. 
5.1.2. Concertation is required when a given R&D activity, such as 
biotechnology, is located in many different centres of both 
decision making and implementation, separated by institutional 
boundaries. Different types of concertation can be identified 
within this general area : 
- Intercountry concertation. 
- Interinstitutional concertation. 
- Intrainstitutional concertation. 
- Interdisciplinary concertation. 
5.1.3. In order to effect the previous types of concertation the 
following activities are required : 
I.Information gathering and dissemination/communication. This 
activity implies locating and storing the right type of 
information, identifying relevant audiences who might be 
interested in it, and adapting and communicating the information 
to those audiences. 
2.Act as an operational linkage helping in setting up and 
implementing decision making processes involving institutional 
81 centres which are for most other purposes separate and 
independent. This could happen for example by means of the 
establishment of committees or working parties with a joint 
membership from the different interacting institutions. Even 
this activity involves gathering and communicating information 
but in addition it contains a 'catalytic' role in starting and 
contributing to the implementation of some actions. 
5.1.4. These requirements for concertation are not unique to 
biotechnology or to BAP but they are common to many if not to all 
other research programmes. What may be different for 
biotechnology could be both the degree of interdisciplinary 
interaction required to advance the research frontier in this 
area and the number and type of centres involved in decision 
making and implementation. Evidence that the diversity of 
sources of information that could be generally classified as 
belonging to biotechnology is particularly great is provided in 
the ASFRA Report"
1 which stresses the extremely large number of 
publications and of professional fields to which they belong. 
This makes the task of keeping up with new developments even more 
difficult than for most other fields of study. Again, although 
this situation is not unique to biotechnology the extent to which 
it is true here may be higher than in most other fields. 
Furthermore one could argue that for a field of knowledge 
(involving many disciplines) as broad and as new as biotechnology 
(see section 2.1) institutional boundaries may be particularly 
fluid and it is at this stage that the greatest extent of 
concertation is required. 
5.1.5. In summary it is quite possible that the optimum extent of 
concertation is higher for biotechnology than for other R&D areas 
and programmes. This would justify the differential importance 
Franklin, J. "The role of information technology and services in 
the future competitiveness of Europe's bio-industries", ASFRA, 
Edam (NL), Jan 1988. 
82 given to it within BAP. Furthermore some aspects of concertation 
activity have been given renewed importance by the recent Single 
European Act (see for example Article 130-1, which provides for a 
framework programme of R&D activities, and 130-N, which provides 
for cooperation with third countries and international 
organisations.) 
5.2. The tasks oiven to CUBE 
5.2.1. If we accept that concertation is a particularly important 
activity in biotechnology then the problem becomes that of 
identifying the specific concertation actions required in 
biotechnology and BAP and the institutional responses which these 
requirements should be given. Now the Council decision setting 
up BAP
a identified for the concertation activity two goals and 
nine tasks. These goals and tasks are related to the previous 
types of concertation activity, as the following examples show : 
1. Intercountry concertation: between different member states of 
the EC (task 4), between the EC and less developed countries 
(task 6). 
2. Interinstitutional concertation: between industry and 
universities (task 4), with the European Federation of 
Biotechnology (EFB) and with the European Biotechnology 
Coordination Group (EBC6) (task 9). 
3. Intrainstitutional concertation: between different Commission 
services (tasks 3, 5 and 7). 
4. Interdisciplinary concertation: this was not prominent amongst 
the tasks set for CUBE, at least in the sense of concertation 
a O.J. N° L83, 25.3.85, pp 1-7. 
83 between different scientific disciplines. On the other hand 
tasks 1,3,7 and 8, requiring the monitoring and gathering of 
information about the social, economic and legal aspects of 
biotechnology require concertation between scientific 
disciplines and the social sciences. 
5.2.2. With respect to the two activities in para 5.1.3. above, CUBE 
has carried out an information-gathering activity (CUBEDOC), has 
acted as secretariat for BRIC*, has contributed to the design of 
programmes like ECLAIR and FLAIR, has contributed to the setting 
of agricultural price regimes in 1985 etc. A complete list of 
all CUBE'S activities and actions would be pointless here, and 
interested readers are referred to CUBE'S 1984-8 report. Uhat is 
immediately clear from the list of tasks and activities of CUBE 
is the extremely wide scope of both of them. This very wide 
scope could give rise to different modes of institutional 
implementation which can be analysed in terms of three 
dimensions: 
Size/resources : Large Small 
Organisational style : 
Formal/bureaucratic flexible/entrepreneurial 
Role : Implementation Catalytic 
In terms of these three dimensions CUBE has so far been small, 
flexible/entrepreneurial and catalytic. 
5.2.3. We have been very impressed by the energy and dedication of the 
members of CUBE that we have met and by the very large number of 
initiatives in which they have been involved. Host of these 
activities are so important that a reasonable share of the 
* Biotechnology Regulations Interservice Committee. 
84 responsibility for their success would be enough to justify 
CUBE'S existence. Ue can give as examples the setting of the 
agricultural price regimes in 1985 and the BRIC committee. 
However, ue have to admit that the evaluation of CUBE presents 
particular difficulties. Ue would like to offer some 
observations about these difficulties not with a negative aim but 
in order to point out some ways in which CUBE'S activities could 
be improved. 
5.2.4. For example a catalytic role is very difficult to evaluate due to 
the impossibility of running a control experiment without the 
catalyst. In other words it is extremely difficult to determine 
CUBE'S share of responsibility for the success (or failure) of 
the activities in which it has been involved. The only way to do 
this would be to obtain the opinion of the members of the 
institutions with which CUBE has interacted in the process of 
concertation. Ue talked to a number of Commission officials from 
outwith DG XII (see Annex 7), but the C6C delegates, 
industrialists, contractors and fellows whom we saw hardly 
mentioned CUBE. Uhile it must be recognised that to be 
evaluated is not the aim of any institution the previous 
observations point to a problem of institutional identity and 
image for CUBE. It is particularly difficult to answer questions 
such as : Uhat is CUBE ? Uhat has it done ? However the 
individual staff of CUBE seem to be better known than CUBE 
itself. 
5.2.5. In what follows we have tried both to make some comments and to 
pose questions generally applicable to all CUBE'S activities, 
and to offer some observations specific to particular activities 
and actions. However, we have not attempted to examine 
systematically all of CUBE'S activities. 
85 5.3. CUBE'S Performance of its tasks 
5.3.1. Diversity/scope of tasks : at present CUBE'S limited resources 
are spread over a very wide variety of tasks. Are they spread 
too thinly? Mould it be better to concentrate on a smaller 
number of better-defined tasks? 
5.3.2. Status : some of the concertation activities in which CUBE is 
involved (e.g. BRIO require the simultaneous presence of 
different Directors-General of the Commission. When such 
concertation activities have to lead to some form of 
implementation (e.g. regulations) delays resulting from 
ineffective concertation can be very serious. What would be 
required in these situations is a decision maker (person or 
institutional subset) having the status required to obtain a 
relatively rapid outcome. The problem arises of either giving 
CUBE this status or of creating different institutional 
mechanisms to improve this type of concertation activity. 
5.3.3. CUBEDOC. This is a database consisting of periodicals, articles, 
reports by other organisations (e.g. OTA, OECD) about 
biotechnology, mission reports etc. It now contains more than 
21,000 items. However we have the impression that the database 
is not well organised or easy to access, and that therefore that 
it does not reach many potential users. Consequently we 
recommend that CUBEDOC should be re-examined with a view to its 
improvement or discontinuance. 
5.3.4. Public opinion. The importance of public opinion has been 
stressed by CUBE members as well as by other biotechnology 
commentators. Given the importance of the issue, it might be 
necessary to include in CUBE communication specialists having 
professional skills in the use of the media required to reach the 
general public. Some of CUBE'S existing literature seems to us to 
be too complicated and even we found it difficult to digest. 
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5· University-industry collaboration. This activity has so far had 
very low prominence. To the extent that it is considered an 
important CUBE task it should be strengthened. 
5·
3·
6· Future orientation/scop^, At present CUBE'S tasks seem to be 
more oriented towards concertation of existing activities. Ue 
wonder whether in order to perform more effectively its role as a 
'catalyst* it would not be better for CUBE for incorporate some 
longer-term forecasting activities in biotechnology. 
5.4. Small biotechnology firms 
5.4.1. Ue believe that there is clear evidence of a need to stimulate 
greater activity in the biotechnology small firm sector and that 
there is a role for the Commission to play in such stimulation on 
the European scale. 
5.4.2. The Commission already has a number of programmes aimed at the 
needs of small and medium-sized firms "SMEs" (i.e. fewer than 500 
employees). 
- the Commission's Task Force on SMEs 
- support for Business and Innovation Centres (BIO in Member 
States and the European Business Network (EBN) through DG XVI 
- the COHETT programme for cooperation between universities and 
enterprises for training in technology, run by D6 V 
- the investments made by the European Investment Bank, which 
works closely with DG II and XVIII 
- the initial support for the European Venture Capital 
Association (from DG XIII) 
- the SPRINT programme to aid transnational technology transfer 
to SMEs, run by DG XIII 
Any fresh initiative should therefore take the form of a 
concertation of the existing programmes (including also national 
schemes), in order to focus on biotechnology SMEs. Such a 
87 focussed initiative may well identify gaps in the programmes and 
it should be an early objective to identify any such gaps and to 
formulate means to fill them. The operational costs for the 
concertation activity and for the formulation of subsequemnt 
programmes would be borne by the budget for concertation, which 
we have recommended should be expanded under BRIDGE. 
5.4.3. The overall objective, through focussing on the biotechnology 
industries, would be to maximise the European (ie transnational) 
impact in the stimulation of SME activity, so assisting them to 
operate in a continental dimension. 
5.5. Summary 
5.5.1. Ue consider that concertation activity is particularly important 
in biotechnology and therefore that there should be a unit like 
CUBE. 
5.5.2. CUBE has been given a large number of tasks. Ue have been very 
impressed with the great energy and resourcefulness of CUBE'S 
members and with the large number of initiatives in which they 
have been involved. However we find that CUBE'S performance 
could be improved by a clearer definition and reduction in the 
number of its tasks. 
5.5.3. An improvement in the Commission's decision-making mechanism is 
needed for major problems that affect more than one DG. CUBE can 
identify them, but they need a Task Force, distinct from CUBE, 
for their resolution. CUBE should retain the small, flexible and 
entrepreneurial structure it has had so far. 
88 ANNEX ó 
BIBLIOMETRIC STUDY OF BEP PUBLICATIONS 
6.1. Summary 
6.1.1. The bibliometric study was set up to examine the transnationalitv 
of BEP papers as compared with other European biotechnology 
papers, and their scientific influence as determined by their 
citation record compared with other papers in the same scientific 
journals. 
6.1.2. The study identified some 420 BEP papers published in or accepted 
by refereed journals by mid -1988. Of these 420, 260 were 
identified through a questionnaire and 31*4 had a trans-national 
authorship. Many of the BEP papers (probably 190, of which 177 
were identified) were published in 10 leading .journals named in 
the BEP Final Report. The papers by EC authors in these journals 
with a trans-national authorship averaged 7% over the years 1981-
87 and this figure was sensibly constant during the period. Thus 
it appears that BEP papers were several times more trans-
national than other EC biotechnology papers published in leading 
journals. 
6.1.3. The BEP provided only a small amount of the overall support for 
biotechnology in the EC while it was in operation. During the 
four main years for BEP publications (1983-6), they only 
represented about 4% of the total output of EC biotechnology 
research, as represented by papers in the 10 journals. However 
for several countries, notably Belgium and Ireland, BEP papers 
represented a much larger fraction than 4% of biotechnology 
research output. 
6.1.4. Biotechnology papers in the 10 journals have a distinctive 
citation pattern, which peaks 2-3 years after publication and 
thereafter declines with a 4-5 year half-life. BEP papers in the 
same journals have a similar pattern, but the average numbers of 
89 citations are almost uniformly higher, by some 40%. 
6.1.5. Comparisons were made of the relative impacts (through the 
cumulative numbers of citations in the five years after 
publication) of particular groups of papers published in 1983. 
Multi-nationally authored EC papers were more highly cited than 
single-nation papers by 75%, and EC papers as a whole were more 
highly cited than those from the rest of the world by 29%. These 
factors largely account for the better citation record of BEP 
papers noted in the previous paragraph. 
6.2. Background and terms of reference 
6.2.1. The use of bibliometric studies in the assessment of research is 
still not universally accepted, partly because publications in 
refereed journals, which are the subject of the studies, are only 
one of the outputs of a research programme. In particular, 
commercial exploitation is not covered. In some research 
domains, the principal results may be communicated through 
conferences, whose literature is usually less accessible and is 
sometimes described as 'grey'. However biotechnology research 
seemed to us to be worth examination by means of a study of its 
output publications. The work in BEP (and also in BAP) was very 
largely of a 'public' nature with open publication being sought, 
and the final report on it published by the Commission indicated 
that a significant percentage of all the publications occurred in 
just 10 journals. These were listed by Dr Magnien, the editor, as 
being both prestigious and frequently used by BEP authors : they 
are given in para 6.3.3. below. 
6.2.2. We therefore arranged for a study to be undertaken for us by Dr 
Paul Cunningham of the Programme of Policy Research in 
Engineering, Science and Technology (PREST), University of 
Manchester. The study was interactive, and the terms of 
90 reference changed somewhat in the light of the results he 
obtained, but it was mainly designed to answer two questions : 
- are BEP papers more trans-national in their authorship than 
other biotechnology papers with EC authors? 
- have BEP papers been cited by other publications at least as 
often as comparable biotechnology papers in the same journals? 
For the purposes of this study, a BEP paper was defined as one 
where the author acknowledged, either publicly or privately, some 
support from the programme. These papers were produced both by 
contractors, and by the fellows and their supervisors. 
6.2.3. Each of the above questions is in the form of a comparison, and 
therefore the study needed to examine what would be an 
appropriate reference group of papers for the purpose. This 
proved to be quite a difficult task. The problem of selection of 
a fair comparison sample is one reason why the results of 
bibliometric studies are not accepted universally. Neverthless 
we consider that the results to be presented are sufficient to 
enable us to answer the two questions with a high degree of 
confidence. 
6.3. Sources of information 
6.3.1. It was necessary to compile as complete a list as possible of the 
BEP papers. This was made up from four sources : 
- responses to a questionnaire sent by Dr Cunningham to all the 
BEP contractors and supervisors of BEP fellows. 
- examination of all EC-authored papers in the 10 journals for an 
acknowledgement to BEP as a source of funding. 
- the lists of publications given in the BEP final report. 
- lists of publications given by BEP fellows who answered our own 
questionnaire (see para 4.4) 
91 6.3.2. Dr Cunningham's questionnaire was returned by about 48% of 
addressees (by 28 June), 57 contractors (52%) and 17 supervisors 
(42%). It elicited specific information on the nationality of 
the authors of some 260 papers in refereed journals, and this 
information was used to answer the first question in para 6.2.2. 
Of these papers, some 95 were published in the 10 journals; the 
other 165 were published in a wide variety of journals
1 but none 
had more than nine papers, whereas six of the 10 exceeded this 
figure. 
6.3.3. The 10 journals are as follows : 
EMBO Journal 
Enzyme Microbial Technology 
Gene 
Journal of Bacteriology 
Molecular and General Genetics 
Nature (biotechnology papers only) 
Nucleic Acids Research 
Plant Molecular Biology 
Plasmid 
Theoretical and Applied Genetics 
(EMBO J.) 
(Enz. Mier. Tech.) 
(Gene) 
(J. Bacter.) 
(Mol. Gen. Genet.) 
(Nature) 
(Nuc. Acid. Res.) 
(Plant Mol. Biol.) 
(Plasmid) 
(Theor. App. Gen.) 
6.3.4. During the five years 1983-7, these 10 journals contained a total 
of 136 papers where specific acknowledgement was made to BEP. 
However there were an additional 41 papers identified from the 
questionnaire and the BEP final report in the 10 journals, so 
evidently between a quarter and a third of BEP authors did not 
The other main journals used were : 
Carlsberg Research Communications 9 papers 
Journal of General Microbiology 9 papers 
Applied Environmental Microbiology 7 papers 
Biochimie, Current Genetics, FEMS Microbiology letters 5 papers 
Plant Science, Proc. NY Academy of Science 5 papers 
Biotechnology Letters, Plant Cell Reports, Planta 4 papers 
92 acknowledge the programme. For the citation analysis, the 
combined list of 177 papers was used. Numbers were as follows : 
Journal  83 84 85 86 87 Total 
EMBO J. 
Enz.Micro.Tech. 
Gene 
J. Bacter. 
Hol.Gen.Genet 
Nature 
Nuci.Acid.Res. 
Plant Mol.Biol. 
Plasmid 
Theor.Appi.Gen. 
Total 
4 
0 
2 
4 
6 
1 
2 
4 
1 
5_ 
29 
5 
2 
4 
6 
5 
3 
1 
5 
2 
1 
34 
9 
1 
7 
8 
14 
4 
10 
7 
2 
4 
66 
5 
2 
6 
4 
8 
1 
5 
1 
2 
_4_ 
38 
1 
1 
2 
2 
2 
0 
0 
1 
0 
1 
10 
24 
ó 
21 
24 
35 
9 
18 
18 
7 
15 
177 
6.3.5. 
Other 
sources 
A final total of 420 BEP publications was identified: this is a 
large majority of those that have been accepted for publication 
so far. The totals can be broken down as follows : 
From Other Number Probable 
questionnaire sources listed total 
All journals 
10 journals 
260 
95 
+ 
+ 
160 
82 
= 420 
= 177 
/ 540 
/ 190 
coverage 
78% 
93% 
Probable total 
Other sources 
(BEP final report) 
Questionnaire 
(48X response) 
93 6.4. Results : transnational itv 
6.4.1. The authorship of BEP papers by the number of Member States
8 
represented, based on the 260 papers in refereed journals 
itemized in the questionnaire responses, was as follows : 
Number of M. S. 
Year 
1983 
84 
85 
86 
87 
88 
Total 
1 
13 
27 
47 
33 
34 
26_ 
180 
2 
5 
5 
16 
18 
15 
10. 
69 
3 
0 
1 
2 
3 
5 
0_ 
11 
% mu 
28 
18 
28 
39 
37 
28 
31 
lti-state 
Thus almost one-third of the papers (in the 48% sample) have a 
trans-national authorship. There is however no obvious trend for 
this proportion to increase over time. Of these 260 papers, 
231 were from contractors and 56, or 24%, had multi-state 
authorship. Among the 95 papers in the 10 journals, however, the 
multi-state authorship was 40 (42%), or 29 (36%) from the 
contractors. 
6.4.2. The questionnaire also asked whether there had been assistance 
through the provision of biological material or equipment by a 
laboratory or from scientists in another EC Member State. 82 
answered 'yes', or 32%; this figure included 45 papers where the 
authorship was from a single country. A total of 134 papers had 
been assisted by discussions with, or other similar forms of 
contribution from, scientists in another Member State (52%). 
The total figure for trans-national cooperation in BEP amounted 
to 68%, made up as follows : 
a Excluding Spain and Portugal, which did not take part in BEP. 
94 Total papers 260 
Multi-EC authorship 80 
Single MS authors with : 
material /equipment 45 
discussions 87 
less both (35) 
177 = 68% 
Again, papers in the 10 listed journals scored more highly : 
among the 55 single M.S. papers, 9 had received 
material/equipment, 24 discussions, and 8 both so a further 25/55 
= 45% should be added to the 42% with multi-state authorship to 
give a total of 87%. 
6.4.3.  For a comparison with the above, the 10 journals were examined 
for the five years 1983-7 and also for 1981 (before BEP began) to 
determine : 
- the total numbers of papers 
- the number where the address of the first-named author was in 
the EC 
- the number where there were authors* addresses from more than 
one EC Member State 
- the numbers where acknowledgement was made to loans from or 
discussions with scientists in another Member State. 
The results were 
Year 
1981 
1983 
1984 
1985 
1986 
1987 
Total 
Total 
papers 
2252 
2975 
3161 
3412 
3378 
3720 
18898 
as follows : 
EC first 
author 
660 
1001 
1076 
1157 
1095 
1281 
6270 
Multi 
EC 
46 
68 
74 
87 
73 
88. 
436 
EC 
loans 
16 
20 
27 
31 
21 
12. 
147 
EC 
talks 
11 
11 
14 
20 
12 
12. 
82 
% 
multiEC 
7.0 
6.8 
6.9 
7.5 
6.7 
L·!.  6.9 
95 6.4.4. It is clear to us from the above table that, although there has 
been an increase in numbers of multi-EC authored papers over the 
period (almost a doubling), the proportion of the total EC output 
has been remarkably constant at 7%. The EC total contribution to 
the journals is close to one-third and is also sensibly constant 
over the seven years. However the BEP papers are very much more 
transnational, whether one considers the total sample of 260, or 
the 95 published in the same 10 journals. 
6.4.5. As mentioned above, there are many BEP papers that do not 
acknowledge their funding source, but we estimate the numbers in 
the 10 journals during the four years 1983-6 to have been about 
178, so BEP has probably contributed to the support of about 4% 
of the 4329 EC papers in the 10 journals in the four principal 
years of its output. This is one measure of the influence of the 
programme on European biotechnology research. Nevertheless, the 
strong transnationality exhibited by BEP papers does not seem to 
have caused a noticeable change in the overall percentage. In 
1985, the peak year for BEP, with a probable total of about 71 
papers in the 10 journals, possibly an extra 23 were trans-
national, which is 2% of the EC total. Yet the percentage for 
that year was only 0.5% higher than in 1981. This suggests that 
BEP may have captured existing trans-national cooperations 
without increasing them significantly. 
6.4.6. The figure of 4% given above represents several times the ratio 
of BEP funding to other sources in the same years. This is 
because the research contracts were only funded at 50%, and our 
interviews with contractors revealed that EC funding generally 
represented a much lower proportion than this of the research 
groups' resources. Nevertheless, EC funding may be significant 
for some Member States. The breakdown by Member State of the EC 
first-author papers for the 10 journals in 1983-6 gives the 
following result : 
96 Total papers  BEP papers
3
 
Β 
D 
OK 
F 
GR 
I 
IRL 
L 
NL 
UK 
147 
1193 
100 
890 
3 
179 
33 
0 
444 
1372 
26 
24 
7 
32 
0 
16 
5 
0 
29 
28 
18V. 
2% 
7% 
4% 
9% 
15% 
7% 
2% 
/&mmm 
^τ^%T>T*Tt%T^T+.♦τ*^^+.♦.♦*+τ♦
,%■
,'■' 
EC papers in 18 journals 1983-6 
OK 
F 
BEP papers in cane Journals and years 
Thus we see that BEP has been particularly important for Belgium 
and Ireland, a conclusion that agrees strongly with the evidence 
given to us during our missions. 
6.5. Results : citations 
6.5.1. The counts of citations given below are all taken from the 
"Science Citation Index" published annually by the Institute for 
Scientific Information in Philadelphia, which covers some 3500 
journals and is regarded as the most comprehensive existing 
There are some significant biasses here, notably the under-
representation of Denmark because many Danish papers appeared in 
Carlsberg Research Communications 
97 tabulation. It contains some slight linguistic biasses, but these 
will be insignificant here as all 10 of the journals studied are in 
English and indeed our study showed that hardly any BEP papers were 
written in other languages. 
6.5.2. One immediate difficulty that we faced because the time and budget 
available for our study were restricted was that the numbers of 
citations of any comparison cohort to the BEP papers could vary 
greatly, depending on whether it contained one very highly-cited 
paper, whose citation counts could exceed those of the rest of the 
cohort put together. The result would be that the average citation 
pattern might be unduly high (or low). There are several statistical 
techniques to tackle this problem : they involve a mechanical 
transformation of the actual values before they are averaged. The 
technique used by Dr Cunningham was to transform the number of 
citations per paper per year,X1, to a new variable X2 where : 
X2 = tfcXI + 0.5) 
The mean value of X2 across a sample cohort of papers from the same 
year and same journal was then calculated (X2) with its standard 
error SE2
4. The mean value was then retransformed to X3 where 
_ 2 
X3 = X2 - 0.5 
and the standard error of X3 calculated (approximately) as 
SE3 = 0.5 ((X2 + SE2)
2 - (X2 - SE2)
2) 
= 2.X2.SE2. 
The value X3 is an unbiassed estimate of the mean of X1, but with a 
smaller standard error. 
6.5.3. The citation numbers of BEP papers were not transformed and then re-
transformed because the papers represented the entire cohort, or at 
least all the papers from the journals known to derive from BEP. In 
practice, as mentioned earlier, it was probably about a 93% sample. 
This is related to the standard deviation of X2 by the formula 
SE2 = SD2/ VÑ. There is a 68% chance that the true value of X2 
is within one standard error of X2. 
98 The actual numbers of citations received by all the papers in the 
five year cohorts were as follows : 
83 cohort 84 cohort 
Journal Ν 83 84 85 86 87 Ν 84 85 86 87 
EMBO J 
Enz.Mier.Tech 
Gene 
J.Bacter. 
Mol.Gen.Genet. 
Nature 
Nuc.Acid.Res. 
Plant Mol.Biol. 
Plasmid 
Theor.Appi.Gen 
Total 
4 
0 
2 
4 
6 
1 
2 
4 
1 
5 
29 
2 
-
0 
4 
2 
5 
2 
0 
0 
2 
17 
9 
-
5 
12 
34 
16 
16 
10 
2 
18 
122 
85 cohort 
10 
-
18 
25 
37 
23 
17 
21 
11 
35 
197 
4 
-
27 
14 
44 
34 
10 
13 
10 
Jà. 
180 
7 
-
33 
23 
42 
36 
9 
18 
10 
13 
191 
86 
5 
2 
4 
6 
5 
3 
1 
5 
2 
_L 
34 
cohort 
9 
0 
0 
7 
0 
9 
1 
0 
4 
1 
31 
47 
2 
15 
28 
18 
59 
15 
6 
9 
__2. 
201 
57 56 
5 6 
20 37 
46 41 
27 20 
73 44 
23 21 
21 14 
12 20 
3_ 3. 
261 242 
87 cohort 
Journal Ν 
EMBO J 9 
Enz.Mier.Tech. 1 
Gene 7 
J.Bacter. 8 
Mol.Gen.Genet. 14 
Nature 4 
Nuc.Acid.Res. 10 
Plant.Mol.Biol. 7 
Plasmid 2 
Theor. Appi. Gen. _4_ 
Total 66 
85 86 87 Ν 86 87 
20 88 99 5 10 42 
0 2 0 2 0 2 
8 23 36 6 5 25 
8 31 34 4 5 9 
14 65 74 8 6 26 
26 96 90 1 1 1* 
9 46 60 5 0 8 
4 17 40 1 0 3 
2 5 20 2 15 
_2_ -20. -IL _J_ _Q_ -± 
93 393 490 38 28 138 
Ν 87 
1 
1 
2 
2 
2 
0 
0 
1 
0 
0 
1 
2 
1 
2 
10 
2. 
8 
β 83 
83 cohort 
8 84  IB 56 87 
84 cohort 
m  β 85 86 87 
83 cohort 
β βΤ 
iii 
M  Φ. 
låi 
87 
86 cohort 
99 6.5.4. The pattern of citations, which, as we shall see, is also typical 
of the reference sample cohorts, is for the numbers per paper 
per year to build up to a peak in the second or third year after 
publication, and then for the numbers slowly to decline. The 
total number of citations to all the BEP papers in the 10 
journals in each year is shown in the diagram below, together 
with the numbers of papers and the pattern of financial 
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100 commitments and payments. This shows that the scientific impact of 
BEP was still rising in 1987. (Estimates based on the citation 
patterns of similarly-sized cohorts of reference papers in the same 
journals for 1977 - see para 6.5.7 - have been made : these indicate 
a peak for BEP citations in 1988 and thereafter a decline.) 
6.5.5. Any comparison of the BEP papers' citation record must be with 
papers that have been "exposed" for citation for precisely the same 
length of time. However we can see from the numbers involved that 
it should be possible to assess the influence of a group of papers 
quite well after only, say, three years even though they will by 
then have received fewer than half of their expected total numbers 
of citations. 
6.5.6. We had some difficulty in choosing the reference cohorts, as we were 
again constrained by time and cost to limit the numbers of papers to 
be examined. Ue decided to take cohorts from two years, 1977 and 
1983. The 1977 cohort allowed us to determine the citation pattern 
for biotechnology papers over a span of ten years, and thus to gain 
an insight into the longevity of papers in what is considered to be 
a rapidly-devloping field. The 1983 cohort allowed us to compare 
the changes in average numbers of citations, year by year, over a 
span of years : we know that many more biotechnology papers were 
published in 1987 than in 1981 (say), but there was correspondingly 
a larger "pool" of papers that could have been cited, both 
cumulatively and within (say) the last three years. 
6.5.7. Three of the 10 journals were not published in 1977, so for these Dr 
Cunningham took a sample of 60 papers, or their first year's output 
if less, from their first year (EMBO J, 1982; Enz Microb Tech, 1979; 
Plant Hol. Biol, 1981). For the others he took 60 papers spread 
through 1977, or the year's output if less (Gene,38; Plasmid,45). 
For the 1983 cohort, a sample of 50 papers from each journal was 
taken, to give a comparable total number. In addition, all the 
101 remaining multi-EC authored papers from the cohort of 68 (see para 
6.3.3) had their citation records determined so that it would be 
possible to compare the respective performance in terms of citations 
for papers with authors from : 
- more than one EC Member State 
- just one EC Member State 
- elsewhere in the world. 
6.5.8. The results were as follows for the 1977 cohort : 
Journal Year: 77 78 79 80 81 82 83 84 85 86 
EMBO J X3 0.82 4.88 7.12 5.80 4.70 
(N=60) SE3 - 0.18 0.60 0.77 0.72 0.69 
Enz Mier Tech X3 0.35 1.08 0.99 0.96 0.76 0.59 0.84 0.40 
(N=23) SE3 - - 0.15 0.28 0.24 0.31 0.25 0.21 0.26 0.11 
Gene X3 0.75 4.90 7.28 7.43 5.76 4.38 3.72 2.99 2.99 2.20 
(N=38) SE3 0.16 1.21 2.06 2.64 2.35 2.12 2.05 1.91 1.76 1.48 
J.Bacteriol X3 0.64 2.46 3.16 3.03 2.63 1.90 1.58 1.36 1.49 1.30 
(N=60) SE3 0.13 0.31 0.38 0.38 0.39 0.31 0.26 0.22 0.25 0.21 
Mol Gen Genet X3 0.55 2.13 2.67 2.55 1.87 1.26 1.33 0.83 0.98 0.70 
(N=60) SE3 0.14 0.34 0.46 0.46 0.37 0.29 0.32 0.25 0.32 0.24 
Nature X3 1.88 8.60 10.3 8.48 5.55 5.18 3.56 3.26 2.44 2.51 
(N=60) SE3 0.46 1.57 1.77 1.50 0.93 0.86 0.52 0.50 0.45 0.45 
NUC Acid Res X3 1.02 3.49 4.79 3.98 2.93 2.39 1.88 1.34 0.93 0.83 
(N=60) SE3 0.22 0.44 0.64 0.59 0.52 0.44 0.37 0.27 0.21 0.18 
Plant Mol Biol X3 - - - - 0 0.47 1.73 3.50 3.26 2.72 
(N=20) SE3 - - - - 0 0.25 0.60' 0.88 0.93 0.97 
Plasmid X3 0.03 1.42 4.01 5.31 4.69 3.95 3.80 3.27 2.74 2.19 
(N=45) SE3 0.03 0.25 0.47 0.72 0.67 0.72 0.79 0.78 0.72 0.62 
Theor Appi Gen X3 0.15 0.44 0.87 0.77 0.69 0.71 0.65 0.44 0.63 0.53 
(N=60) SE3 0.05 0.12 0.19 0.13 0.15 0.15 0.15 0.14 0.15 0.12 
The pattern of a peak of citations after two-three years that was 
shown by the BEP papers (para 6.5.4) is very clear, see diagram 
below. Thereafter the number of citations halves every three-five 
years, with the highly-cited journals like "Gene" and "Nature" being 
102 more "short-lived". It is also clear that there is a big variation 
between journals in average citations, the extremes being 
represented by "Nature" and "Theor. Appi. Gen." with respectively 
10.3 and 0.9 citations per paper on average in the second year after 
publication. 
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103 6.5.9.  For the 1983 cohort, the results were as follows (N=50 except for 
"Plant Mol. Biol.") : 
Journal Year : 83 84 85 86 87 
EMBO J 
Enz Mier Tech 
Gene 
J Bacter 
Mol Gen Genet 
Nature 
Nuci Acid Res 
Plant Mol Biol 
Plasmid 
Theor Appi Gen 
1.15 
0.27 
0.46 
0.83 
0.65 
2.18 
0.83 
0.06 
0.57 
0.35 
4.81 
0.78 
2.61 
2.85 
3.15 
12.2 
4.91 
1.49 
2.74 
1.46 
6.28 
1.55 
3.16 
2.88 
3.12 
13.9 
5.23 
3.63 
2.55 
2.13 
5.44 
1.30 
3.20 
2.28 
2.57 
11.4 
4.84 
3.53 
2.46 
1.96 
4.26 
1.09 
2.24 
2.81 
2.44 
8.24 
4.03 
2.75 
1.87 
1.82 
6.5.10. The pattern of citations is very similar to that for the 1977 
cohort, but the average number per paper in the five years after 
publication has increased overall by 11.4%, on the basis of means 
weighted by the numbers of papers in each journal in 1983 although 
for four journals the numbers of citations have gone down, notably 
for "Gene" and "Plasmid". 
Nature paper citations 1977 cohort 
Β 848586 8T 
1983 cohort 
The citation patterns against which BEP papers published in the five 
104 years 1983-7 should be compared have therefore been calculated on 
the basis of a linear increase of 1.9?. per year (i.e., one sixth of 
the change between the 1977 and 1983 cohorts) applied from 1980, or 
the appropriate later year for journals first published after 1977, 
to the means of the numbers given in the two above tables. 
For example, the reference citation patterns for "Nature" are as 
follows : 
Citation year 
Publication 83 84 85 86 87 
year 
1983 2.26 11.6 13.5 11.1 7.68 
1984 2.30 11.8 13.8 11.3 
1985 2.35 12.0 14.0 
1986 2.39 12.3 
1987 2.44 
6.5.11. We can now calculate the expected numbers of citations for a 
reference cohort of papers published in the same year as the BEP 
cohort, and consisting of the same numbers in each of the 10 
journals. These may be compared directly with the figures in the 
table in para 6.5.3. Ue give below only the totals and the mean 
values per paper : 
Citation year 
83 84 85 86 87 
Publication total mean total mean total mean total mean total mean 
year 
1983 BEP 17 0.6 122 4.2 197 6.8 180 6.2 191 6.6 
Ref. 0.6 3.1 4.1 3.8 3.2 
1984 BEP 31 0.9 201 5.9 261 7.7 242 7.1 
Ref. 0.8 3.8 5.0 4.6 
1985 BEP 93 1.4 393 5.9 490 7.4 
Ref. 0.8 3.9 5.0 
1986 BEP 28 0.7 138 3.6 
Ref. 0.8 3.7 
1987 BEP 8 0.8 
Ref. 0.6 
105 br y gr sr 
83 cohort 
1983 comparison cohort 
« ST 86 
cohort 85 cohort 
Mean citations of BEP papers 
Κ 86 8T 
1984 cohort 
β 85 86  87 
1989 cohort 
86 cohort 
4-
1986 cohort 
6.5.12. He have also estimated the standard errors of the means given in the 
above table caused by the comparison cohorts not being fully 
representative of the whole population, and they are very much 
smaller than the differences between the means for the BEP papers 
and the control cohorts. For example, for 1983 BEP papers cited in 
1985, the standard error of the mean is 0.7, and the BEP paper 
citations exceeded the expected value by 2.7, or nearly four times 
the standard error of the latter. We may thus conclude that, as far 
as ue can determine at present, BEP papers have had a significantly 
higher influence on biotechnology research than have average papers 
in the same journals. The ratio appears to be of the order of 1.4 
to one, that is, BEP papers received on average 40% more citations 
than other papers published in the same journals. 
6.5.13. Ue also obtained data on the relative numbers of citations of multi-
EC authored papers, single Member State papers, and non-EC papers 
106 (see the table in para 6.4.3, and para 6.5.6) for 1983 publication. 
We weighted the mean citation numbers in two ways, First, in order 
to compare multi-EC papers with one M.S. papers, we used the numbers 
of EC papers comprised in the table in para 6.4.3. Then in order to 
compare EC papers with those from the rest of the world we weighted 
the numbers of citations by the numbers of all papers comprised in 
the same table. The results were as follows : 
Citation in : 
Multi-EC (N= 68) 
Single-EC (N=184) 
X1 
X3 
83 
1.9 
0.9 
84 
7.3 
4.8 
85 
8.8 
5.4 
86 
8.6 
4.7 
87 
7.7 
3.7 
10 
"83 84 85 86 8T 
Citations of milti-EC papers 
Citation in : 83 
EC authors (N=252) X3 1.0 
Rest of World (N=290) X3 0.8 
β 83 84 85 86 87 
Citations of single-EC papers 
84 85 86 
4.9 
3.8 
5.5 
4.4 
4.9 
3.7 
87 
4.1 
3.2 
83 84 85 86 87 
Citations of papers by EC authors 
β 83  84  85  86  87 
Citations of papers from rest of Morid 
107 For the latter table, the values for "EC authors" have been taken as 
0.93 χ single EC authors + 0.07 χ multi-EC authors, to reflect the 
overall balance of these papers. 
6.5.14. The above tables suggest that there are real differences in mean 
numbers of citations between EC papers with authors from more than 
one, and just one, Member State, and also between EC papers and 
those from the rest of the world (predominantly the US). The 
ratios, based on five years' citations, are 1.75 and 1.29. These 
differences must account for a large part of the higher citation 
record of BEP papers found in para 6.5.12. BEP papers are, by 
definition, of EC origin, and they are also heavily trans-national 
(especially those in the 10 journals, see para 6.4.1). Application 
of the two ratios above (1.75, 1.29) to a random sample composed of 
58% single-EC papers and 42% multi-EC papers would in fact suggest a 
citation record 1.5 times better than the journal average. This is 
surpassed by the 1983-85 BEP cohorts: it is perhaps too soon to draw 
conclusions about the 1986 and 1987 BEP papers. 
6.6. Hiqhiv-cited BEP Papers 
6.6.1. In the course of the analysis, we identified some BEP papers that 
received large numbers of citations, and may therefore represent 
scientific work of outstanding merit. We give below the full 
references of 14 papers, four each for 1983,84 and 85, and two from 
1986, which headed the lists of citations for their years. 
6.6.2. From the 1983 cohort: 
Hoekema, Α., Hirsch, P.R., Hooykaas, P.J.J, and Schilperoort, R.A. A 
binary plant vector strategy based on separation of virând T-region of 
the Agrobacterium tumefaciens Ti-plasmid. Nature, vol. 303, 179-
180.(114 citations) 
108 Petit.A., David,C, Dahl,G.Α.., Ellis, J.G., Guyon,P., Casse-Delbart, 
F., Tempé, J. Further extension of the opine concept: Plasmids in 
Aqrobacterium rhizogenes cooperate for opine degradation. Mol. Gen. 
Genet., vol. 190, 204-214. (69 citations) 
Downie, J.Α., Hombrecher, G., Ma, Q-S., Knight, CD., Wells, B. & 
Johnston, A.W.B. Cloned nodulation genes of Rhizobium Lequminosarum 
determine host range specificity. Mol. Gen. Genet, vol. 190, 359-365 
(.63 citations) 
Bagdasarian M.M., Amann E., Lurz R., Rückert Β., and Bagdasarian M. 
Activity of the hybrid trp-lac (tac) promoter of Escherichia coli in 
Pseudpmonas putida. Construction of broad host range controlled 
expression vectors. Gene vol. 26, 273-282. (52 citations) 
6.6.3. From the 1984 cohort: 
De Block, M., Herrera-Estrella, L., Van Montagu, Μ., Schell, J., and 
Zambryski.P. Expression of foreign genes in regenerated plants and in 
their progeny. EMBO J. vol. 3,1681-1689 (96 citations) 
Herrera-Estrella, L., Van Den Broeck, G., Maenhaut, R., Van Montagu, 
M., Schell, J., Timko, M. and Cashmore, A. Light-inducible and 
chloroplast-asssociated expression of a chimeric gene introduced into 
Nicotiana tabacum using a Ti plasmid vector. Nature vol. 310, 115-120 
(93 citations) 
Hooykaas-Van Slogteren, G.M.S., Hooykaas, P.J.J, and Schilperoort, 
R.A. Expression of Ti plasmid genes in monocotyledonous plants 
infected with Aqrobacterium tumefaciens. Nature vol. 311, 763-764. 
(61 citations) 
Rossen,L., Johnston, A.W.B. & Downie, J.A. DNA sequence of the 
Rhizobium lequminosarum nodulation genes nodAB and C_ required for root 
hair curling. Nucl. Acids Res. vol. 12, 9497-9508. (60 citations) 
109 6.6.4. From the 1985 cohort: 
Stachel, S.E., Messens, E., Van Montagu, M. and Zambryski, P. 
Identification of the signal molecules produced by wounded plant cells 
that activate T-DNA transfer in Agrobacterium tumefaciens Nature vol. 
318, 624-629 (77 citations) 
Van Den Broeck, G., Timko, M.P., Kausch, A.P., Cashmore, A.R., Van 
Montagu, Μ., and Herrera-Estrella, L. Targeting of a foreign protein 
to chloroplasts by fusion to the transit peptide of ribulose-1,5-
bisphosphate carboxylase. Nature vol. 313, 358-363 (75 citations) 
Koukolikova-Nicola, Z., Shillito, R.D., Hohn, Β., Uang, Κ., Van 
Montagu, M., and Zambryski, P. Involvement of circular intermediates 
in the transfer of T-DNA from Agrobacterium tumefaciens to plant 
cells. Nature vol. 313, 191-196 (58 citations) 
Downie, J.Α., Knight, CD., Johnston, A.U.B. & Rossen, L. 
Identification ot genes and gene products involved in the nodulation 
of peas by Rhizobium leguminosarum. Mol. Gen. Genet, vol. 198, 225-
262. (42 citations) 
6.6.5. From the 1986 cohort: 
Shearman, C.A., Rossen, L., Johnston, A.U.B., & Downie, J.A. The 
Rhizobium leguminosarium gene nodF encodes a polypeptide similar to 
acyl-carrier protein and is regulated by nodD plus a factor in pea 
root exudate. EMBO J. vol. 5, 647-652. (28 citations) 
Jensen, J.S., Marcker, K.A., Otten, L., and Schell, J. Nodule-
specific expression of a chimaeric soybean leghaemoglobin gene in 
trangenic Lotus corniculatus. Nature, vol 321, 669 (15 citations) 
6.6.6. By way of comparison, the top 4 papers from the 1983 comparison 
cohorts from "EMBO J.", "Mol. Gen. Genet.", and "Nature" had the 
following numbers of citations in the 2,3,4, and 5 years after 
publication : 
110 EHBO J. 
Mol. Gen. 
Nature 
1 
2 
3 
4 
Genet. 1 
2 
3 
4 
1 
2 
3 
4 
36 
37 
26 
15 
12 
11 
11 
13 
85 
19 
52 
34 
77 
75 
56 
47 
26 
21 
22 
24 
159 
57 
86 
66 
126 
112 
100 
89 
36 
32 
33 
31 
254 
95 
109 
107 
172 
137 
128 
128 
49 
46 
39 
38 
330 
145 
131 
127 
6.6.7. We conclude from the above comparison that the two 1983 BEP papers in 
"Mol. Gen. Genet." were outstanding for that journal, although modest 
in comparison with papers in, say, "EMBO J.". Among the 1984 BEP 
papers, the first two were among the top four or five for their year 
and journal (i.e. the top 10%). The 1985 BEP cohort fared better, and 
all of the four listed would have been among the top 10% for their 
year (notably the last one, in "Mol Gen. Genet." which had nearly 
twice the citations in a three-year period of the leading four in 
that journal). 
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PERSONS MHO GAVE EVIDENCE TO THE PANEL 
7.1. ORAL EVIDENCE 
7.1.1. Commission officials (DG XII unless otherwise noted) 
A. Aguilar 
R. Batti 
U. Bertazzoni 
H. Cantiey 
G. del Bino 
D. de Nettancourt 
I. Economidis 
G.L. Ferrerò 
U. Floyd 
A. Goffeau 
P. Gray 
S. Keegan 
A. Klepsch 
Ε. Hägnien 
R. Petrella 
A. Saint Rémy 
K. Sargeant 
Β. Schmitz 
Β. Traill 
F. Van Hoeck 
Β. von Uüllerstorff 
DG VIII 
DG XI 
DG XVII 
DG VI 
DG III 
DG III 
7.1.2. Members and former members of CGC 
A. Albert (E) 
R.H. Aram (UK) 
F.J.A. Carvalho Guerra (Ρ) 
J. de Brabandère (Β) 
113 D. Jonas (UK) 
M. Lelong (F) 
A.F. Lott (UK) 
K.A. Harcker (DK) 
I. Petersen (DK) 
P. Printz (F) 
J. Ryan (IRL) 
CE. Sekeris (6R) 
D. Thomas (F, ex-Chairman) 
A.S. Tsaftaris (6R) 
H.C.F, van den Bosch (NL) 
R.R. van der Meer (NL, Chairman) 
H.C. van der Plas (NL, ex-Chairman) 
E. Warmuth (D) 
7.1.3. Contractors and their representatives. (6BI = BEP contracts) 
(BAP-0019 -B) 
(GBI-3-106-B, BAP-0048-B) 
(BAP-0121 -B) subcontract 
(GBI-4-065-B, BAP-0248-D) 
(BAP-0028-UK) 
BELGIUM. 
M. Boutry/M. Briquet 
J. Davison 
P. d'Oultremont 
W. Fiers 
G.L. Hennebert 
J.P. Hernalsteens/H. De Greve (BAP-0089- B) 
CM. Lapiere (BAP-0278- B) 
J. Limet (BAP-0123- B) 
N.M. Nolard-Tintigner/C.Vuncks(BAP-0028-UK) 
J. Rommelaere (BAP-0121- B) 
P.G. Rouxhet/Navamoses (GBI-1-006-B, BAP-0069-B) 
DENMARK 
B.S. Adamsen/K. Kleiding 
A. Brandt 
R. Rajagopal/J. Marchison 
(BAP-0023-DK) 
(GBI-4-024-DK, BAP-0025-DK, BAP-0091-DK) 
(BAP-0077-DK) 
114 FRANCE 
J.P. Bourgin 
J. Cohen 
6. Corvier 
Y. Dattee 
L. Dubertret 
F. Dufau/D. Duval 
H. Fukuhara 
H. Guerineau 
L.M. Houdebine 
J. Janin/S. Baudet 
A. Koutoujansky 
J.C. Mercier 
V.M. Nigon 
A. Panneggiarli 
Β. Perret 
R.J. Poljak 
F. Quetier/B. Lejeune 
M. Weiss 
R.6. Uhalen/P. Herbomel/S. 
(GBI-6-071-F) 
(GBI-2-080-F, BAP-0156-F) 
(BAP-0144 -F) 
(BAP-0014 -F) 
(BAP-0277 -F) 
(BAP-127-F) 
(GBI-2-093-F, BAP-0026-F) 
(GBI-2-081-F, BAP-0268-F) 
(BAP-01079-F) 
(BAP-0049 -F) 
CBAP-0212 -F) 
(GBI-2-082-F) 
(GBI-2-126-F, BAP-0124 -F) 
(BAP-0066 -F) 
(BAP-0031 -F) 
(BAP-0221 -F) 
(GBI-4-104-F, BAP-0022 -F) 
(BAP-0017 -F) 
Cereghini/F. Tronche (BAP-0145 -F) 
GERMANY 
C. Bachem/L. Moore (BAP- 102-UK) 
A. Böck/D. Sizroan/C. Kalman (BAP-0040 -0) 
G. Cesaren! 
R. Cortese 
Κ. Esser/F. Meinhardt 
F. Götz 
Κ.D. Kulbe 
H.P. Lepers/Fluggen 
H. Lörz 
H.J. Rziha 
C. Sander 
P. Schreier 
W.L. Standenbauer 
(BAP-0252 -D) 
(BAP-0115 -D) 
(GBI-4-102-D) 
(BAP-0196 -D) 
(BAP-0059 -D) 
(BAP-0033 -D) 
(BAP-0013 -D) 
(GBI-2-056-D, BAP-0233- D) 
(BAP-0227 -D) 
(BAP-0096 -D) 
(BAP-0045 -D) 
115 P. Starlinger (GBI-4-130-D) 
R. Thompson (BAP-0213 -D) 
R. uingender-Drissen/F.Kreuzaler (BAP-0087 -D) 
IRELAND 
D. Higgins 
D. Mc Connell 
M. 0'Connell 
(BAP-0137-IRL) 
(GBI-2-092-IRL, BAP-0263-IRL) 
(BAP-0080-IRL) 
ITALY 
P. Arosio 
L. D'Angiuro 
G. Carrea 
H. Motto 
S. Riva 
F. Sala 
A. Vecchi 
(ΒΑΡ-0246 -I) 
(GBI-1-075-1) 
(GBI-1-051-I, BAP-0065-I) 
(BAP-02U -I) 
(BAP-0122 -I) 
(BAP-0084 -I) 
(BAP-0273 -I) 
THF. NETHERLANDS 
L. Bosch 
U.M. De Vos 
C.J. Keijzer 
(BAP-0057 -NL) 
(GBI-2-084-NL, BAP-0011 -NL) 
(BAP-0202 -NL) 
H.J.J. Nijkamp 
P.H. Pouwels 
U.F. Stevens/H.Nieboer/P. Van Lelyveld (GBI-1-077-NL, GBI-3-063-NL, 
BAP-0251-NL, BAP-0109 -NL) 
(GBI-4-110-NL, GBl-3-061-NL, BAP-0020-NL) 
(GBI-2-009-NL, GBI-5-118-NL, BAP-0064 -NL, 
BAP-0018-NL) 
(BAP-0202 -NL) 
(GBI-4-109-NL, BAP-0083-NL) 
(BAP-0083 -NL) 
(BAP-0202 -NL) 
C.H. Theunis 
W.Van der Valk/W.Verhuizen 
L. van Vloten-Doting 
H.J. Wilms 
UNITED KINGDOM 
R. Barr 
C.J. Bostock 
(BAP-0280 -UK) 
(BAP-0237 -UK) 
116 F. Broun (GBI-2-053-UK, BAP- 232 -UK) 
R. Casey (GBI-4-113-UK, BAP-0063 -UK) 
R.B. Flavell/V. Colot/A. Goldsbrough/M. Thomas 
(GBI-4-027-UK, GBI-4-115-UK, BAP-0106-UK) 
B. Gillham (BAP-0284 -UK) 
B. Hartley (BAP-0265 -UK) 
D.L. Hawksworth/D.Allsopp/D. Smith (BAP-0004 -UK, BAP-0028-UK) 
L.R. Hill/H. Costas/V. Hughes/L. Sloss (BAP-0138 -UK, CBAP-0002 -UK) 
P. Hirsch (BAP-0024 -UK, BAP-0100 -UK) 
R. Hull (BAP-0097 -UK) 
A.W.B. Johnston (GBI-5-070-UK) 
M.G.K. Jones (GBI-4-023-UK, BAP- 101 -UK) 
M. Kreis (BAP-0099 -UK) 
H.D. Lilly (GBI-1-008-UK) 
K. Miller/Gangoly/Hard (BAP-0272 -UK) 
E.R. Pike (BAP-0293 -NL) 
F. Stewart (GBI-2-088-UK) 
7.1.4. Current fellows under BAP 
V. Blank (D) 
B. Carpentier (F) 
M. Crozatier (F) 
P. Eraso (E) 
P. Fiorentini (I) 
G. Godin (F) 
H. Hoffman (D) 
Ν. Houba-Herin (Β) 
Η. Kavanagh (IRL) 
Ν. Leduc (F) 
A. Luzzago (I) 
J.A.S.P. Matos (Ρ) 
P. Ottaviani (F) 
B. Papadopoulou (GR) 
A. Phanopoulos (GR) 
117 F. Pinto (E) 
F. Portillo (E) 
E. Tinois (F) 
G. Soldevilla (E) 
V. Sophianopoulos (GR) 
U. Schmitz (D) 
M. Storrs (IRL) 
E. Yagüe (E) 
7.1.5. Supervisors of fellows (nationality / host country) 
P. Borst (NL) 
P. Brown (UK) 
G. Cesarini (I/D) 
R. Cortese (I/D) 
F. Brunei (B) 
G. Douglas (IRL) 
. Dufour (Β) 
T. Gaspar (Β) 
A. Goffeau (Β) 
T. Graf (D) 
L.A. Grevell (UK/NL) 
S. Hartley (UK) 
M.C. Kielland-Brandt (DK) 
D. Lonsdale (UK) 
L. Luzzato (UK) 
M.E. Selkirk (UK) 
A.D. Smith (UK) 
M. Stanley (UK) 
P. Stariinger (D) 
H. ten Cate (NL) 
P. Trieu-Cuot (F) 
118 7.1.6. Former fellows under BEP 
C. Gebhardt (D) 
S. Giovenco (I) 
R. Götz (D) 
C. Hussey (IRL) 
E. Jackson (UK) 
K. Larsen (DK) 
J. Nicaud (F) 
B. Nieuwenhuis (NL) 
M. Verhoeyen (B) 
7.1.7. Industrial representatives 
Β.S. Adamsen, Danish Distillers A/S (DK) 
J. Britton, Irish Sugar Co (IRL) 
F. Brown, «eliconie Biotechnology Ltd (UK) 
A. Bruggink, OCE. Andeno NV (NL) 
B. Cantwell, Guinness Co Ltd (IRL) 
P. d'Oultremont, Solvay S.A. (Β) 
F. Dufau and D. Duval, Bertin et Cie (F) 
A. Formigoni, Sipcam Spa (I) 
G. Freyssinet, Rhone-Poulenc S.A. (F) 
D. Gunary, Nickerson Seed Co Ltd (UK) 
J. Herrman, Glaxo pic (UK) 
J. Leemans, Plant Genetic Systems NV (B) 
J.H. Mahler, Novoindustri A/S (DK) 
P. Niebes, Searle (B) 
M. Hilmer Nielsen, Novoindustri A/S (DK) 
S. Paleoyannis, Biohellas Hellenic Biotechnology Cie (GR) 
S. Petersen, Novoindustri A/S (DK) 
K. Powell, ICI pic (UK) 
H. Soria, Farmitalia Spa (I) 
A. Stavropoulos, Vioryl SA (GR) 
P. Van den Elzen, Mogen International BV (NL) 
119 R. van der Meer, HOM NV (NL) 
F. Vecchio, ORIS Spa (I) 
7.1.8. Other persons 
N.H. Axelsen, Statens Seruminstitut, Kobenhavn, (DK) 
C. Christiansen, Gensplejsningsgruppen, Lyngby, (DK) 
R. Dietz, Laboratory of the Government Chemist, London (UK) 
P.O. Larsen, Forskningskirektoratet, Kobenhavn (DK) 
L. Philipson, EMBL, Heidelberg (S) 
U.F. Stevens, Medical Biological Laboratory, TNO Rijswijk (NL) 
M. Tsogas, Ministry of Industry, Athinai (6R) 
J.N. Wingfield, Agricultural and Food Research Council, London (UK) 
7.2. WRITTEN EVIDENCE 
7.2.1. Commission officials 
M. Cantley (XII-F-1) 
G. del Bino (XI-A-2) 
W.B. Traill (XII-H-2) 
W. Floyd (VI-01) 
7.2.2. Former fellows under BEP (questionnaire) 
A. Athanassiadou (GR) 
A. Bacolla (I) 
G. Bensi (I) 
M. Charbonnier (F) 
F. Chauvat (F) 
T. Cogan (IRL) 
C. Crétin (F) 
M. Crouzet (F) 
M. de Crombrugghe (B) 
120 T. Delaunay (F) 
U.M. de Vos (NL) 
A. di Pietro (F) 
F. Duras (D) 
P. Durrens (F) 
J.P. Dyson (UK) 
5. Junker (DK) 
S.S. Hanian (UK) 
6. Romeo (I) 
L. Sibold (F) 
J.H. Tempelaar (NL) 
P. Woolley (UK) 
7.2.3. Industrial representatives (questionnaire) 
6. Alexander, Transgene SA (F) 
Aline, Doittau EmuIdo (F) 
Κ. Ashley, Hast Laboratories Ltd. (UK) 
C.P.U. Boeder, Sensys (NL) 
W.H. Boldingh, Akzo Pharma BV (NL) 
G.A. Brooker, Celltech Ltd (UK) 
A. Capelle, Avebe BA (NL) 
R. Chabannes, Hero-Rousselot-Satia (F) 
H. Chmiel, Fraunhofer Institut (D) 
U.B. Christie, Premier Breeders Ltd (UK) 
R. Connett, Agricultural Genetics Co plc (UK) 
K. Coupland, Croda Universal Ltd (UK) 
D. Czeschlik, Springer-Verlag (D) 
C.H.M.M. De Bruijn, Euro-Diagnostics BV (NL) 
Η. Delaage, Immunotech (F) 
U.H. De Niet, Sanbio BV (NL) 
A.C. De Ruiter, De Ruiter Zonen (NL) 
P. Desmettre, Rhone Herieux (F) 
R.A. Dicker, Dairy Crest Ltd. (UK) 
H. Dubois, Sanofi-Elf-Bio-Recherches (F) 
121 H. Durand, Cayla (F) 
L. Flohé, Gruenenthal GmbH (D) 
J.E. Fonteyne, Centocor Europe BV (NL) 
CR. Franks, Euro Cetus BV (NL) 
Α. Frouin, Lab. Soredab (F) 
U.U. Gerard, Cambridge Life Sciences plc (UK) 
M. Gervais and J.M. Le Moullec, Roussel Uclaf (F) 
P. Giordano, Bio Rad Laboratories SRL (I) 
G.I. Glikmans, Technip (F) 
P.J.F. Hack, Paques BV (NL) 
Α. Hamilton, Amersham International pie (UK) 
G. Hubert, Institut de Selection Animale (F) 
E.J. Hudson, Albright & Wilson Ltd (UK) 
M.H. James, Shield Diagnostics Ltd (UK) 
J.P. Jarry, Lafarge Coppe (F) 
H. Kloft, Biotest Pharma GmbH (D) 
R. Kron-Morelli, Agrifutur (I) 
K. Koerts, Suiker Unie Research (NL) 
P. Koning, Holland Biotechnology BV (NL) 
H.G. Kooreman, International Bio-Synthetics BV (NL) 
H. Kragen, Mero-Rousselot-Satia (F) 
R.U.F. Le Page, Biotal Ltd (UK) 
W. Leuchtenberger, Degussa AG (D) 
H.C.G. Ligtenberg, Sentron VOF (NL) 
J.P. Mégnin, Moët-Hennessy-Louis-Vuitton (F) 
E.M. Meijer, DSM Research (NL) 
J-C. Morell, La Cellulose du Pin SA (F) 
A.D. Mulder, Royal Sluis BV (NL) 
Nordmann, Bayer AG (D) 
S. Paleoyannis, Biohellas SA (GR) 
F. Parenti, Lepetit Research Centre (I) 
K.H. Pelster, Millipore GmbH (D) 
G.S. Plastow, Dalgety pic (UK) 
M.H. Pranger, Duphar BV (NL) 
R. Reiner, Röhm GmbH (D) 
122 F.H. Roberts, Bioprocessing Ltd (UK) 
P.J. Rodgers, ICI pic (UK) 
A.J. Savill, Fermentech Ltd. (UK) 
H.U. Schenck, BASF AG (D) 
Schöls, Siemens AG (D) 
J.F. Seitzer, Kleinwanzlebener Saatzucht AG (D) 
J.J. Snoijink, Nordic Immunological Laboratories (NL) 
Sonneveld, DSM (NL) 
B. Spruijtenburg, HWZ Bodemsauering (NL) 
J. Tretzel, Akzo Research Laboratories (D) 
J. Van Burg, Applikon Dependable Instruments BV (NL) 
Van Weperen, Bio-Intermediair BV (NL) 
J.E. Veldhuyzen van Zanten, Zaadunie BV (NL) 
Vente, Euribrid (Β) 
J.A.J. Vink, CSM biological division (NL) 
G. Volpe, RASA - Realtur Spa (I) 
Wandrey, Nuclear Research Centre Jülich (D) 
T.J. Warren, L.H. Fermentation Ltd (UK) 
A. Weber, Schering AG (D) 
J. Winter, COMASSO (D) 
Anonymous : - Laboratoire Barreret et Ducloux (F) 
- Courtaulds Research (UK) 
7.2.4. Other persons 
J.M. Bove, Association pour le développement des biotechnologies en 
Aquitaine (F). 
E. Drioli, Società Chimica Italiana (I). 
J. Hamill, Cruachem Ltd (UK). 
U.A. Hamilton, University of Aberdeen (UK). 
P. Monsan, Association pour le Développement de la Bio-Industrie (F) 
C. Ratledge, University of Hull (UK). 
K. Schügerl, Universität Hannover (D). 
R. Shewry, Rothamsted Experimental Station (UK). 
C. Shirlaw, Scottish Development Agency, (UK). 
123 D.A. Stafford, Society for Applied Bacteriology (UK). 
G.J. Stegehuis, Centraalbureau voor Schimmelcultures (NL). 
C.M. Thomas, University of Birmingham (UK). 
K.N. Tiromis, Gesellschaft für Biotechnologie Forschung mbH (D) 
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LIST OF DOCUMENTS CONSULTED BY THE PANEL 
8.1. Extracts from the Official Journal 
1. Council Decision of 7 December 1981 (BEP) 
L 375, 30.12.81, pp 1-4 
2. Council Decision of 26 October 1983 (BEP, second stage) 
L 305, 8.11.83, pp 11-13 
3. Council Decision of 12 March 1985 (BAP) 
L 83, 25.3.85, pp 1-7 
8.2. Commission documents 
1. Proposal for a Council Decision (BEP) 
COM (79) 793 final, 11 January 1980 
2. Proposal for a Council Decision (BAP) 
COM (84) 230 final, 26 April 1984 
3. Review of BAP 
COM (86) 272 final, 21 May 1986 
4. A Community framework for the regulation of biotechnology. 
COM (86) 573 final, 4 November 1986 
5. Proposal for revision of BAP 
COM (87) 481 final/2, 19 November 1987 
6. Proposal for a Council Decision (ECLAIR) 
COM (87) 667 final, 18 December 1987 
125 7. Proposal for a regulatory framework for the use of genetically 
modified organisms. 
COM (88) 160, 29 March 1988 
8. Proposal for a Council Directive on the protection of workers 
from the risks related to exposure to biological agents at work. 
COM (88) 165 final - SYN 129, 5 April 1988 
8.3. Commission publications 
1. Research and training programme in biomolecular engineering : 
catalogue of contracts with classification of activities. 
EUR 9857, 1985. 
2. Biomolecular engineering in the European Community, E. Magnien 
(Ed); Martinus Nijhoff, Dordrecht (NL); EUR 10658, 1986. 
3. BEP/BAP/Biotechnology, (brochure) 
4. Biotechnology Action Programme (1985-1989) : 
catalogue of contracts with classification of activities, 
Β Nieuwenhuis (Ed), EUR 10954, 1988. 
5. Biotechnology Action Programme, Progress report 1987, E. Magnien 
(Ed), volumes 1 and 2, EUR 11138, 1988. 
6. Vade-mecum of Community research promotion. 
CD-46-86-266-EN-C, 1987. 
7. STD/Science and Technology for Development (brochure). 
126 8.4. Commission mimeographs 
1. BEP and BAP : press cuttings on activities and results during the 
period 1984-1987. 
2. Training activities implemented in the framework of the 
Biomolecular Engineering Programme. 
3. Training activities implemented in the framework of the 
Biotechnology Action Programme : the opinion of trainees and of 
training supervisors. 
M. Mongini and D. de Nettancourt. 
4. Risk assessment for the release of genetically manipulated micro-
organisms. Meeting papers, Bayreuth, October 26-28, 1987. 
5. IRDAC opinion on future R&D programmes in the field of 
biotechnology, December 1987. 
6. In vitro evaluation of the toxicity and pharmacological activity 
of molecules, Meeting papers. Bad Irsee, March 30 - April 1, 
1988. 
7. CUBE report, 1984-1988 : retrospect and prospect. Draft of 9 
March 1988. 
8. The future of the European food system : implications for science 
and technology policy. Executive summary of FAST study, February 
1988. 
9. Science and Technology for Development, 1987-91. Information 
file. 
10. BAP: Autopsy of a call for proposals. Facts and Statistics. June 
1988. 
127 8.5. Miscellaneous 
1. "What regulatory framework for biotechnology in Europe ?" 
Proceedings of a seminar held by Centre for European Policy 
Studies, Brussels, 23 February 1988. 
2. "Rhizobium leguminosarum as a model for investigating gene 
transfer in soil". PR Hirsch and JR Spokes. In : "Risk 
assessment for deliberate release", ed. : Ualter Klingmüller; 
Springer-Verlag, 1988. 
3. "The impact of biotechnology on European agriculture". 
6. Junne, with J. Bijman. University of Amsterdam, Department of 
International Relations and International Public Lau, 31 August 
1987. 
4. "Mapping our genes. The genome projects : how big, how fast ?" 
Office of Technology Assessment, Washington DC, April 1988. 
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(1982-1986) and the Biotechnology Action Programme-BAP 
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Ch. af Malmborg, P. Feiltet, F. Kafatos, J. Koeman, P. Saviotti, 
F. Schmidt-Kästner, G. Walker 
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